

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/57, 15/75, 9/54, C12K 14/00	A2	(11) International Publication Number: WO 98/56927 (43) International Publication Date: 17 December 1998 (17.12.98)
(21) International Application Number: PCT/US98/12005 (22) International Filing Date: 9 June 1998 (09.06.98) (30) Priority Data: 08/873,479 12 June 1997 (12.06.97) US (71) Applicant: NOVO NORDISK BIOTECH, INC. [US/US]; 1445 Drew Avenue, Davis, CA 95616-4880 (US). (72) Inventors: SLOMA, Alan; 849 Donovan Court, Davis, CA 95616 (US). CHRISTIANSON, Lynne; 722 Barcelona Avenue, Davis, CA 95616 (US). (74) Agents: ZELSON, Steve, T. et al.; Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY 10174 (US).		(81) Designated States: AL, AU, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LU, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i> <i>With an indication in relation to deposited biological material furnished under Rule 13bis separately from the description.</i>
(54) Title: NUCLEIC ACIDS ENCODING POLYPEPTIDE HAVING PROTEASE ACTIVITY (57) Abstract The present invention relates to isolated acid sequences from <i>Bacillus</i> encoding polypeptides having protease activity. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as recombinant methods for producing the polypeptides.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NUCLEIC ACIDS ENCODING POLYPEPTIDES HAVING PROTEASE ACTIVITY

5

Cross-Reference to Related Applications

This application is a continuation-in-part of pending U.S. application Serial No. 08/873,479 filed on June 12, 1997, which application is fully incorporated herein by reference.

10

Background of the Invention

Field of the Invention

15 The present invention relates to isolated nucleic acid sequences encoding polypeptides having protease activity. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as recombinant methods for producing the polypeptides.

20 Description of the Related Art

Detergents formulated with proteolytic enzymes are known to have improved properties for removing stains. For example, SAVINASE™ (Novo Nordisk A/S, Bagsvaerd, Denmark), a microbial protease obtained from *Bacillus lentus* has been introduced into many commercial brands of detergent.

25 WO 88/01293 discloses proteases obtained from an alkalophilic *Bacillus* species having enhanced stability towards bleaching agents of the peroxy type.

JP 1497182 discloses a DNA sequence encoding an alkaline protease Y from *Bacillus* which is said to have good alkali and surfactant resistance and improves detergency.

Many detergents are alkaline in solution (*e.g.*, around pH 10). There is a need for new
30 proteolytic enzymes with high activity at high pH which are stable towards bleaching agents. Proteases of the type disclosed in WO 88/01293 possess these characteristics, and therefore, are highly desirable for use in detergent compositions. Heretofore, however, there has been no means of producing these enzymes recombinantly.

It is an object of the present invention to provide for recombinant production of these
35 valuable enzymes.

Summary of the Invention

The present invention relates to isolated nucleic acid sequences encoding polypeptides having protease activity, selected from the group consisting of:

- 5 (a) a nucleic acid sequence encoding a polypeptide having an amino acid sequence which has at least 95% identity with the amino acid sequence of SEQ ID NO:43;
- (b) a nucleic acid sequence encoding a polypeptide having an amino acid sequence which has at least 85% identity with the amino acid sequence of SEQ ID NO:42;
- (c) a nucleic acid sequence having at least 95% homology with the mature polypeptide
10 encoding region of the nucleic acid sequence of SEQ ID NO:41;
- (d) an allelic variant of (a), (b), or (c); and
- (e) a subsequence of (a), (b), (c), or (d), wherein the subsequence encodes a polypeptide fragment which has protease activity.

The present invention also relates to nucleic acid constructs, vectors, and host cells
15 comprising the nucleic acid sequences as well as recombinant methods for producing the polypeptides.

Brief Description of the Figures

20 Figure 1 shows a restriction map of pShv2.

Figure 2 shows a restriction map of pSJ1678.

Figure 3 shows a restriction map of pSJ2882-MCS.

Figure 4 shows a restriction map of pPL1759.

25 Figures 5A and 5B show the nucleic acid sequence and the deduced amino acid sequence of a *Bacillus* JP170 (NCIB 12513) protease gene.

Figures 6A and 6B show a comparison of the deduced amino acid sequence of a *Bacillus* JP170 (NCIB 12513) protease gene to the deduced amino acid sequences of other proteases.

Figure 7 shows a restriction map of pPL2419.

30 Figure 8 shows a restriction map of pCAsub2.

Figure 9 shows comparative wash results in a model detergent of *Bacillus* sp. JP170 protease and SAVINASE™ in removing grass stain from cotton.

Figure 10 shows comparative wash results in a Koso Top detergent of *Bacillus* sp. JP170 protease and SAVINASE™ in removing grass stain from cotton.

35

Detailed Description of the Invention

Isolated Nucleic Acid Sequences Encoding Polypeptides Having Protease Activity

The term "isolated nucleic acid sequence" as used herein refers to a nucleic acid
5 sequence which is essentially free of other nucleic acid sequences, *e.g.*, at least about 20% pure,
preferably at least about 40% pure, more preferably at least about 60% pure, even more
preferably at least about 80% pure, and most preferably at least about 90% pure as determined
by agarose electrophoresis. For example, an isolated nucleic acid sequence can be obtained by
standard cloning procedures used in genetic engineering to relocate the nucleic acid sequence
10 from its natural location to a different site where it will be reproduced. The cloning procedures
may involve excision and isolation of a desired nucleic acid fragment comprising the nucleic
acid sequence encoding the polypeptide, insertion of the fragment into a vector molecule, and
incorporation of the recombinant vector into a host cell where multiple copies or clones of the
nucleic acid sequence will be replicated. The nucleic acid sequence may be of genomic, cDNA,
15 RNA, semisynthetic, synthetic origin, or any combinations thereof.

In a second embodiment, the present invention relates to isolated nucleic acid sequences
encoding polypeptides comprising an amino acid sequence which has a degree of identity to the
amino acid sequence of SEQ ID NO:43 of at least about 95%, and preferably at least about
97%, which have protease activity (hereinafter "homologous polypeptides").

20 In a third embodiment, the present invention relates to isolated nucleic acid sequences
encoding polypeptides comprising an amino acid sequence which has a degree of identity to the
amino acid sequence of SEQ ID NO:42 of at least about 85%, preferably at least about 90%,
more preferably at least about 95%, and most preferably at least about 97%, which have
protease activity preferably after post-translational processing (also hereinafter "homologous
25 polypeptides").

In a preferred embodiment, the homologous polypeptides have an amino acid sequence
which differs by five amino acids, preferably by four amino acids, more preferably by three
amino acids, even more preferably by two amino acids, and most preferably by one amino acid
from the amino acid sequence of SEQ ID NO:43. For purposes of the present invention, the
30 degree of identity between two amino acid sequences is determined by the Clustal method
(Higgins, 1989, *CABIOS* 5: 151-153) with an identity table, a gap penalty of 10, and a gap
length penalty of 10.

Preferably, the nucleic acid sequences of the present invention encode polypeptides
which comprise the amino acid sequence of SEQ ID NO:42 or SEQ ID NO:43, or an allelic
35 variant thereof. In a more preferred embodiment, the nucleic acid sequences of the present
invention encode polypeptides which comprise the amino acid sequence of SEQ ID NO:42 or

SEQ ID NO:43. In another preferred embodiment, the nucleic acid sequences of the present invention encode a polypeptide which has the amino acid sequence of SEQ ID NO:42 or SEQ ID NO:43 or a fragment thereof, wherein the fragment has protease activity. In a most preferred embodiment, the nucleic acid sequence encodes a polypeptide which has the amino acid sequence of SEQ ID NO:42 or SEQ ID NO:43. The present invention also encompasses nucleic acid sequences which encode a polypeptide having the amino acid sequence of SEQ ID NO:42 or SEQ ID NO:43, which differ from SEQ ID NO:41 by virtue of the degeneracy of the genetic code. The present invention also relates to subsequences of SEQ ID NO:41 which encode fragments of SEQ ID NO:42 or SEQ ID NO:43 which have protease activity.

10 A subsequence of SEQ ID NO:41 is a nucleic acid sequence encompassed by SEQ ID NO:41 except that one or more nucleotides from the 5' and/or 3' end have been deleted. Preferably, a subsequence contains at least 1029 nucleotides, more preferably at least 1119 nucleotides, and most preferably at least 1209 nucleotides. A fragment of SEQ ID NO:42 or SEQ ID NO:43 is a polypeptide having one or more amino acids deleted from the amino and/or carboxy terminus of this amino acid sequence. Preferably, a fragment contains at least 343 amino acid residues, more preferably at least 373 amino acid residues, and most preferably at least 403 amino acid residues.

An allelic variant denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. The term allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.

The amino acid sequences of the homologous polypeptides may differ from the amino acid sequence of SEQ ID NO:42 or SEQ ID NO:43 by an insertion or deletion of one or more amino acid residues and/or the substitution of one or more amino acid residues by different amino acid residues. Preferably, amino acid changes are of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.

Examples of conservative substitutions are within the group of basic amino acids (such as arginine, lysine and histidine), acidic amino acids (such as glutamic acid and aspartic acid), polar amino acids (such as glutamine and asparagine), hydrophobic amino acids (such as leucine, isoleucine and valine), aromatic amino acids (such as phenylalanine, tryptophan and tyrosine), and small amino acids (such as glycine, alanine, serine, threonine and methionine). Amino acid substitutions which do not generally alter the specific activity are known in the art

and are described, for example, by H. Neurath and R.L. Hill, 1979, *In, The Proteins*, Academic Press, New York. The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly as well as these in reverse.

5 In a third embodiment, the present invention relates to isolated nucleic acid sequences which have a degree of homology to the mature polypeptide coding sequence of SEQ ID NO:41 of at least about 95% homology, and preferably at least about 97% homology, which encode a polypeptide having protease activity; or allelic variants and subsequences of SEQ ID NO:41 which encode polypeptide fragments which have protease activity. For purposes of the
10 present invention, the degree of homology between two nucleic acid sequences is determined by the Clustal method (Higgins, 1989, *supra*) with an identity table, a gap penalty of 10, and a gap length penalty of 10.

In a fourth embodiment, the present invention relates to isolated nucleic acid sequences encoding polypeptides having protease activity which hybridize under low stringency
15 conditions, more preferably medium stringency conditions, and most preferably high stringency conditions, with an oligonucleotide probe which hybridizes under the same conditions with the nucleic acid sequence of SEQ ID NO:41 or its complementary strand (J. Sambrook, E.F. Fritsch, and T. Maniatus, 1989, *Molecular Cloning, A Laboratory Manual*, 2d edition, Cold Spring Harbor, New York); or allelic variants and subsequences of SEQ ID NO:41 which
20 encode polypeptide fragments which have protease activity.

The nucleic acid sequence of SEQ ID NO:41, or a subsequence thereof, as well as the amino acid sequence of SEQ ID NO:42 or SEQ ID NO:43, or a partial sequence thereof, may be used to design an oligonucleotide probe to identify and clone DNA encoding polypeptides having protease activity from strains of different genera or species according to methods well
25 known in the art. In particular, such probes can be used for hybridization with the genomic or cDNA of the genus or species of interest, following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein. Such probes can be considerably shorter than the entire sequence, but should be at least 15, preferably at least 25, and more preferably at least 40 nucleotides in length. Longer probes can also be used. Both DNA and
30 RNA probes can be used. The probes are typically labeled for detecting the corresponding gene (for example, with ^{32}P , ^3H , ^{35}S , biotin, or avidin).

Thus, a genomic, cDNA or combinatorial chemical library prepared from such other organisms may be screened for DNA which hybridizes with the probes described above and which encodes a polypeptide having protease activity. Genomic or other DNA from such other
35 organisms may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques. DNA from the libraries or the separated DNA may be transferred to and

immobilized on nitrocellulose or other suitable carrier material. In order to identify a clone or DNA which is homologous with SEQ ID NO:41, the carrier material is used in a Southern blot. Hybridization indicates that the nucleic acid sequence hybridizes to the oligonucleotide probe corresponding to the polypeptide encoding part of the nucleic acid sequence shown in SEQ ID
5 NO:41, under low to high stringency conditions (*i.e.*, prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 µg/ml sheared and denatured salmon sperm DNA, and either 25, 35 or 50% formamide for low, medium and high stringencies, respectively), following standard Southern blotting procedures. The carrier material is finally washed three times each for 30 minutes using 2 x SSC, 0.2% SDS preferably at least 50°C (very low stringency), more
10 preferably at least 55°C (low stringency), more preferably at least 60°C (medium stringency), more preferably at least 65°C (medium-high stringency), even more preferably at least 70°C (high stringency), and most preferably at least 75°C (very high stringency). Molecules to which the oligonucleotide probe hybridizes under these conditions are detected using X-ray film.

The nucleic acid sequences of the present invention may be obtained from
15 microorganisms of any genus. For purposes of the present invention, the term "obtained from" as used herein in connection with a given source shall mean that the polypeptide encoded by the nucleic acid sequence is produced by the source or by a cell in which the nucleic acid sequence from the source has been inserted.

The nucleic acid sequences may be obtained from a bacterial source. For example, the
20 nucleic acid sequences may be obtained from a gram positive bacterium such as a *Bacillus* strain or a *Streptomyces* strain, *e.g.*, *Streptomyces lividans* or *Streptomyces murinus*; or from a gram negative bacterium, *e.g.*, *E. coli* or *Pseudomonas* sp.

In a preferred embodiment, a nucleic acid sequence of the present invention is obtained from a strain of the genus *Bacillus*, as defined by Fergus G. Priest In Abraham L. Sonenshein,
25 James A. Hoch, and Richard Losick, editors, *Bacillus subtilis and Other Gram-Positive Bacteria*, American Society For Microbiology, Washington, D.C., 1993, pages 3-16.

In a more preferred embodiment, the nucleic acid sequences are obtained from a
Bacillus alkalophilus, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus firmus*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus*
30 *megaterium*, *Bacillus pumilus*, *Bacillus stearothermophilus*, *Bacillus subtilis*, or *Bacillus thuringiensis* strain.

In a most preferred embodiment, the nucleic acid sequence is obtained from *Bacillus* strain NCIB 12513, *e.g.*, the nucleic acid sequence set forth in SEQ ID NO:41. In another most preferred embodiment, the nucleic acid sequence is the sequence contained in plasmid.

p170BAN which is contained in *Bacillus subtilis* LC20 NRRL B-21680.

Strains of these species are readily accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL).

Furthermore, such nucleic acid sequences may be identified and obtained from other sources including microorganisms isolated from nature (*e.g.*, soil, composts, water, etc.) using the above-mentioned probes. Techniques for isolating microorganisms from natural habitats are well known in the art. The nucleic acid sequence may then be derived by similarly screening a genomic or cDNA library of another microorganism. Once a nucleic acid sequence encoding a polypeptide has been detected with the probe(s), the sequence may be isolated or cloned by utilizing techniques which are known to those of ordinary skill in the art (see, *e.g.*, Sambrook *et al.*, 1989, *supra*).

The techniques used to isolate or clone a nucleic acid sequence encoding a polypeptide are known in the art and include isolation from genomic DNA, preparation from cDNA, or a combination thereof. The cloning of the nucleic acid sequences of the present invention from such genomic DNA can be effected, *e.g.*, by using the well known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, *e.g.*, Innis *et al.*, 1990, *PCR: A Guide to Methods and Application*, Academic Press, New York. Other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleic acid sequence-based amplification (NASBA) may be used. The nucleic acid sequence may be cloned from a strain of *Bacillus*, or another or related organism and thus, for example, may be an allelic or species variant of the polypeptide encoding region of the nucleic acid sequence.

Modification of a nucleic acid sequence of the present invention may be necessary for the synthesis of polypeptides substantially similar to the polypeptide. The term "substantially similar" to the polypeptide refers to non-naturally occurring forms of the polypeptide. These polypeptides may differ in some engineered way from the polypeptide isolated from its native source. For example, it may be of interest to synthesize variants of the polypeptide where the variants differ in specific activity, thermostability, pH optimum, or the like using, *e.g.*, site-directed mutagenesis. The analogous sequence may be constructed on the basis of the nucleic acid sequence presented as the polypeptide encoding part of SEQ ID NO:41, *e.g.*, a subsequence thereof, and/or by introduction of nucleotide substitutions which do not give rise to another amino acid sequence of the polypeptide encoded by the nucleic acid sequence, but

which corresponds to the codon usage of the host organism intended for production of the enzyme, or by introduction of nucleotide substitutions which may give rise to a different amino acid sequence. For a general description of nucleotide substitution, see, *e.g.*, Ford *et al.*, 1991, *Protein Expression and Purification* 2: 95-107.

5 It will be apparent to those skilled in the art that such substitutions can be made outside the regions critical to the function of the molecule and still result in an active polypeptide. Amino acid residues essential to the activity of the polypeptide encoded by the isolated nucleic acid sequence of the invention, and therefore preferably not subject to substitution, may be identified according to procedures known in the art, such as site-directed mutagenesis or
10 alanine-scanning mutagenesis (see, *e.g.*, Cunningham and Wells, 1989, *Science* 244: 1081-1085). In the latter technique, mutations are introduced at every positively charged residue in the molecule, and the resultant mutant molecules are tested for protease activity to identify amino acid residues that are critical to the activity of the molecule. Sites of substrate-enzyme interaction can also be determined by analysis of the three-dimensional structure as determined
15 by such techniques as nuclear magnetic resonance analysis, crystallography or photoaffinity labelling (see, *e.g.*, de Vos *et al.*, 1992, *Science* 255: 306-312; Smith *et al.*, 1992, *Journal of Molecular Biology* 224: 899-904; Wlodaver *et al.*, 1992, *FEBS Letters* 309: 59-64).

A nucleic acid sequence of the present invention may also encode fused polypeptides or cleavable fusion polypeptides in which another polypeptide is fused at the N-terminus or the C-
20 terminus of the polypeptide or fragment thereof. A fused polypeptide is produced by fusing a nucleic acid sequence (or a portion thereof) encoding another polypeptide to a nucleic acid sequence (or a portion thereof) of the present invention. Techniques for producing fusion polypeptides are known in the art, and include ligating the coding sequences encoding the polypeptides so that they are in frame and that expression of the fused polypeptide is under
25 control of the same promoter(s) and terminator.

Nucleic Acid Constructs

The present invention also relates to nucleic acid constructs comprising a nucleic acid sequence of the present invention operably linked to one or more control sequences which
30 direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences. Expression will be understood to include any step involved in the production of the polypeptide having protease activity including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

35 "Nucleic acid construct" is defined herein as a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which has been modified.

to contain segments of nucleic acid which are combined and juxtaposed in a manner which would not otherwise exist in nature. The term nucleic acid construct is synonymous with the term expression cassette when the nucleic acid construct contains all the control sequences required for expression of a coding sequence of the present invention. The term "coding
5 sequence" as defined herein is a sequence which is transcribed into mRNA and translated into a polypeptide. The boundaries of the coding sequence are generally determined by a ribosome binding site located just upstream of the open reading frame at the 5' end of the mRNA and a transcription terminator sequence located just downstream of the open reading frame at the 3' end of the mRNA. A coding sequence can include, but is not limited to, DNA, cDNA, and
10 recombinant nucleic acid sequences.

An isolated nucleic acid sequence encoding a polypeptide may be manipulated in a variety of ways to provide for expression of the polypeptide having protease activity. Manipulation of the nucleic acid sequence prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying nucleic acid
15 sequences utilizing cloning methods are well known in the art.

The term "control sequences" is defined herein to include all components which are necessary or advantageous for the expression of a polypeptide. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, a propeptide sequence, a promoter, a signal
20 sequence, and a transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a polypeptide. The term "operably linked" is defined herein as a configuration in which a
25 control sequence is appropriately placed at a position relative to the coding sequence of the nucleic acid sequence such that the control sequence directs the production of a polypeptide.

The control sequence may be an appropriate promoter sequence, a nucleic acid sequence which is recognized by a host cell for expression of the nucleic acid sequence. The promoter sequence contains transcriptional control sequences which mediate the expression of
30 the polypeptide. The promoter may be any nucleic acid sequence which shows transcriptional activity in the host cell of choice including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

Examples of suitable promoters for directing the transcription of the nucleic acid
35 constructs of the present invention, especially in a bacterial host cell, are the promoters obtained from the *E. coli lac* operon, the *Streptomyces coelicolor* agarase gene (*dagA*), the *Bacillus*

subtilis levansucrase gene (*sacB*), the *Bacillus licheniformis* alpha-amylase gene (*amyL*), the *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), the *Bacillus amyloliquefaciens* alpha-amylase gene (*amyQ*), the *Bacillus licheniformis* penicillinase gene (*penP*), the *Bacillus subtilis* *xylA* and *xylB* genes, and the prokaryotic beta-lactamase gene (Villa-Kamaroff *et al.*,
5 1978, *Proceedings of the National Academy of Sciences USA* 75: 3727-3731), as well as the *tac* promoter (DeBoer *et al.*, 1983, *Proceedings of the National Academy of Sciences USA* 80: 21-25). Further promoters are described in "Useful proteins from recombinant bacteria" in *Scientific American*, 1980, 242: 74-94; and in Sambrook *et al.*, 1989, *supra*.

The control sequence may also be a suitable transcription terminator sequence, a
10 sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.

The control sequence may also be a suitable leader sequence, a nontranslated region of an mRNA which is important for translation by the host cell. The leader sequence is operably
15 linked to the 5' terminus of the nucleic acid sequence encoding the polypeptide. Any leader sequence which is functional in the host cell of choice may be used in the present invention.

The control sequence may also be a signal peptide coding region, which codes for an amino acid sequence linked to the amino terminus of a polypeptide which can direct the encoded polypeptide into the cell's secretory pathway. The 5' end of the coding sequence of
20 the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide coding region which is foreign to the coding sequence. The foreign signal peptide coding region may be required where the coding sequence does not normally contain a signal peptide
25 coding region. Alternatively, the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to obtain enhanced secretion of the polypeptide. The signal peptide coding region may be obtained from an amylase or a protease gene from a *Bacillus* species, or the calf preprochymosin gene. However, any signal peptide coding region which directs the expressed polypeptide into the secretory pathway of a host cell of choice may
30 be used in the present invention.

An effective signal peptide coding region for bacterial host cells is the signal peptide coding region obtained from the maltogenic amylase gene from *Bacillus* NCIB 11837, the *Bacillus stearothermophilus* alpha-amylase gene, the *Bacillus licheniformis* subtilisin gene, the *Bacillus licheniformis* beta-lactamase gene, the *Bacillus stearothermophilus* neutral proteases
35 genes (*nprT*, *nprS*, *nprM*), or the *Bacillus subtilis* *prsA* gene. Further signal peptides are

described by Simonen and Palva, 1993, *Microbiological Reviews* 57: 109-137.

The control sequence may also be a propeptide coding region, which codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to a mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the *Bacillus subtilis* alkaline protease gene (*aprE*), or the *Bacillus subtilis* neutral protease gene (*nprT*).

Where both signal peptide and propeptide regions are present at the amino terminus of a polypeptide, the propeptide region is positioned next to the amino terminus of the polypeptide and the signal peptide region is positioned next to the amino terminus of the propeptide region.

The nucleic acid constructs of the present invention may also comprise one or more nucleic acid sequences which encode one or more factors that are advantageous for directing the expression of the polypeptide, e.g., a transcriptional activator (e.g., a *trans*-acting factor), a chaperone, and a processing protease. Any factor that is functional in the host cell of choice may be used in the present invention. The nucleic acids encoding one or more of these factors are not necessarily in tandem with the nucleic acid sequence encoding the polypeptide.

A transcriptional activator is a protein which activates transcription of a nucleic acid sequence encoding a polypeptide (Kudla *et al.*, 1990, *EMBO Journal* 9: 1355-1364; Jarai and Buxton, 1994, *Current Genetics* 26: 2238-244; Verdier, 1990, *Yeast* 6: 271-297). The nucleic acid sequence encoding an activator may be obtained from the gene encoding *Bacillus stearothermophilus* NprA (*nprA*).

A chaperone is a protein which assists another polypeptide to fold properly (Hartl *et al.*, 1994, *TIBS* 19: 20-25; Bergeron *et al.*, 1994, *TIBS* 19: 124-128; Demolder *et al.*, 1994, *Journal of Biotechnology* 32: 179-189; Craig, 1993, *Science* 260: 1902-1903; Gething and Sambrook, 1992, *Nature* 355: 33-45; Puig and Gilbert, 1994, *Journal of Biological Chemistry* 269: 7764-7771; Wang and Tsou, 1993, *The FASEB Journal* 7: 1515-11157; Robinson *et al.*, 1994, *Bio/Technology* 1: 381-384; Jacobs *et al.*, 1993, *Molecular Microbiology* 8: 957-966). The nucleic acid sequence encoding a chaperone may be obtained from the genes encoding *Bacillus subtilis* GroE proteins and *Bacillus subtilis* PrsA. For further examples, see Gething and Sambrook, 1992, *supra*, and Hartl *et al.*, 1994, *supra*.

A processing protease is a protease that cleaves a propeptide to generate a mature biochemically active polypeptide (Enderlin and Ogrydziak, 1994, *Yeast* 10: 67-79; Fuller *et al.*, 1989, *Proceedings of the National Academy of Sciences USA* 86: 1434-1438; Julius *et al.*, 1984, ...

Cell 37: 1075-1089; Julius *et al.*, 1983, Cell 32: 839-852; U.S. Patent No. 5,702,934). The nucleic acid sequence encoding a processing protease may be obtained from the genes encoding *Saccharomyces cerevisiae* dipeptidylaminopeptidase, *Saccharomyces cerevisiae* Kex2, *Yarrowia lipolytica* dibasic processing endoprotease (*xpr6*), and *Fusarium oxysporum* metalloprotease (p45 gene).

It may also be desirable to add regulatory sequences which allow the regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems would include the *lac*, *tac*, and *trp* operator systems. Other examples of regulatory sequences are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metallothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the polypeptide would be operably linked with the regulatory sequence.

Expression Vectors

The present invention also relates to recombinant expression vectors comprising a nucleic acid sequence of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleic acid sequence encoding the polypeptide at such sites. Alternatively, the nucleic acid sequence of the present invention may be expressed by inserting the nucleic acid sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression, and possibly secretion.

The recombinant expression vector may be any vector (*e.g.*, a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleic acid sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids. The vector may be an autonomously replicating vector, *i.e.*, a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, *e.g.*, a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into

the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. The vector system may be a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon.

5 The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Examples of bacterial selectable markers are the *dal* genes from *Bacillus subtilis* or *Bacillus licheniformis*, or markers which confer antibiotic resistance such as
10 ampicillin, kanamycin, chloramphenicol, or tetracycline resistance.

 The vectors of the present invention preferably contain an element(s) that permits stable integration of the vector into the host cell genome or autonomous replication of the vector in the cell independent of the genome of the cell.

 For integration into the host cell genome, the vector may rely on the nucleic acid
15 sequence encoding the polypeptide or any other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous recombination. Alternatively, the vector may contain additional nucleic acid sequences for directing integration by homologous recombination into the genome of the host cell. The additional nucleic acid sequences enable the vector to be integrated into the host cell genome at a precise location(s)
20 the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence
25 that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleic acid sequences. On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination.

 For autonomous replication, the vector may further comprise an origin of replication
30 enabling the vector to replicate autonomously in the host cell in question. Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in *E. coli*, and pUB110, pE194, pTA1060, and pAM β 1 permitting replication in *Bacillus*. The origin of replication may be one having a mutation which makes its functioning temperature-sensitive in the host cell (see, e.g., Ehrlich,
35 1978, *Proceedings of the National Academy of Sciences USA* 75: 1433).

More than one copy of a nucleic acid sequence of the present invention may be inserted into the host cell to increase production of the gene product. An increase in the copy number of the nucleic acid sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene with the nucleic acid sequence where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the nucleic acid sequence, can be selected for by culturing the cells in the presence of the appropriate selectable agent.

The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, *e.g.*, Sambrook *et al.*, 1989, *supra*).

Host Cells

The present invention also relates to recombinant host cells, comprising a nucleic acid sequence of the invention, which are advantageously used in the recombinant production of the polypeptides. The term "host cell" encompasses any progeny of a parent cell which is not identical to the parent cell due to mutations that occur during replication.

A vector comprising a nucleic acid sequence of the present invention is introduced into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector. Integration is generally considered to be an advantage as the nucleic acid sequence is more likely to be stably maintained in the cell. Integration of the vector into the host chromosome may occur by homologous or non-homologous recombination as described above.

The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source. The host cell may be a unicellular microorganism, *e.g.*, a prokaryote, or a non-unicellular microorganism, *e.g.*, a eukaryote. Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a *Bacillus* cell, *e.g.*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus firmus*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus stearothermophilus*, *Bacillus subtilis*, or *Bacillus thuringiensis*; or a *Streptomyces* cell, *e.g.*, *Streptomyces lividans* or *Streptomyces murinus*, or gram negative bacteria such as *E. coli* and *Pseudomonas* sp. In a preferred embodiment, the bacterial host cell is a *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus stearothermophilus* or *Bacillus subtilis* cell.

The introduction of a vector into a bacterial host cell may, for instance, be effected by protoplast transformation (see, *e.g.*, Chang and Cohen, 1979, *Molecular General Genetics* 168:

111-115), by using competent cells (see, *e.g.*, Young and Spizizin, 1961, *Journal of Bacteriology* 81: 823-829, or Dubnau and Davidoff-Abelson, 1971, *Journal of Molecular Biology* 56: 209-221), by electroporation (see, *e.g.*, Shigekawa and Dower, 1988, *Biotechniques* 6: 742-751), or by conjugation (see, *e.g.*, Koehler and Thorne, 1987, *Journal of Bacteriology* 169: 5771-5278).

Methods of Production

The present invention also relates to methods for producing a polypeptide comprising (a) cultivating a host cell under conditions suitable for production of the polypeptide; and (b) recovering the polypeptide.

In the production methods of the present invention, the cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art (see, *e.g.*, M.V. Arbige *et al.*, In Abraham L. Sonenshein, James A. Hoch, and Richard Losick, editors, *Bacillus subtilis and Other Gram-Positive Bacteria*, American Society For Microbiology, Washington, D.C., 1993). Suitable media are available from commercial suppliers or may be prepared according to published compositions (*e.g.*, in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it can be recovered from cell lysates.

The polypeptides may be detected using methods known in the art that are specific for the polypeptides. These detection methods may include use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. For example, an enzyme assay may be used to determine the activity of the polypeptide. Procedures for determining protease activity are known in the art and include, *e.g.*, measurement of fluorescence resulting from the hydrolysis of casein labeled with fluorescein isothiocyanate.

The resulting polypeptide may be recovered by methods known in the art. For example, the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.

The polypeptides of the present invention may be purified by a variety of procedures

known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing, differential solubility (e.g., ammonium sulfate precipitation), SDS-PAGE, or extraction (see, e.g., *Protein Purification*, J.-C. Janson and Lars Ryden, editors, 5 VCH Publishers, New York, 1989).

Removal or Reduction of Protease Activity

The present invention also relates to methods for producing a mutant cell of a parent cell, which comprises disrupting or deleting a nucleic acid sequence of the present invention or 10 a control sequence thereof, which results in the mutant cell producing less of the polypeptide encoded by the nucleic acid sequence than the parent cell.

The construction of strains which have reduced protease activity may be conveniently accomplished by modification or inactivation of a nucleic acid sequence of the present invention necessary for expression of the polypeptide having protease activity in the cell. The 15 nucleic acid sequence to be modified or inactivated may be, for example, a nucleic acid sequence encoding the polypeptide or a part thereof essential for exhibiting protease activity, or the nucleic acid sequence may have a regulatory function required for the expression of the polypeptide from the coding sequence of the nucleic acid sequence. An example of such a regulatory or control sequence may be a promoter sequence or a functional part thereof, i.e., a 20 part which is sufficient for affecting expression of the polypeptide. Other control sequences for possible modification are described above.

Modification or inactivation of the nucleic acid sequence may be performed by subjecting the cell to mutagenesis and selecting for cells in which the protease producing capability has been reduced. The mutagenesis, which may be specific or random, may be 25 performed, for example, by use of a suitable physical or chemical mutagenizing agent, by use of a suitable oligonucleotide, or by subjecting the DNA sequence to PCR generated mutagenesis. Furthermore, the mutagenesis may be performed by use of any combination of these mutagenizing agents.

Examples of a physical or chemical mutagenizing agent suitable for the present purpose 30 include ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), O-methyl hydroxylamine, nitrous acid, ethyl methane sulphonate (EMS), sodium bisulphite, formic acid, and nucleotide analogues.

When such agents are used, the mutagenesis is typically performed by incubating the cell to be mutagenized in the presence of the mutagenizing agent of choice under suitable 35 conditions, and selecting for cells exhibiting reduced protease activity or production.

Modification or inactivation of production of a polypeptide encoded by a nucleic acid

sequence of the present invention may be accomplished by introduction, substitution or removal of one or more nucleotides in the nucleic acid sequence or a regulatory element required for the transcription or translation thereof. For example, nucleotides may be inserted or removed so as to result in the introduction of a stop codon, the removal of the start codon, or a change of the open reading frame. Such modification or inactivation may be accomplished by site-directed mutagenesis or PCR generated mutagenesis in accordance with methods known in the art. Although, in principle, the modification may be performed *in vivo*, *i.e.*, directly on the cell expressing the nucleic acid sequence to be modified, it is preferred that the modification be performed *in vitro* as exemplified below.

10 An example of a convenient way to inactivate or reduce production by a host cell of choice is based on techniques of gene replacement or gene interruption. For example, in the gene interruption method, a nucleic acid sequence corresponding to the endogenous gene or gene fragment of interest is mutagenized *in vitro* to produce a defective nucleic acid sequence which is then transformed into the host cell to produce a defective gene. By homologous recombination, the defective nucleic acid sequence replaces the endogenous gene or gene fragment. It may be desirable that the defective gene or gene fragment also encodes a marker which may be used for selection of transformants in which the gene encoding the polypeptide has been modified or destroyed.

Alternatively, modification or inactivation of a nucleic acid sequence of the present invention may be performed by established anti-sense techniques using a nucleotide sequence complementary to the polypeptide encoding sequence. More specifically, production of the polypeptide by a cell may be reduced or eliminated by introducing a nucleotide sequence complementary to the nucleic acid sequence encoding the polypeptide which may be transcribed in the cell and is capable of hybridizing to the polypeptide mRNA produced in the cell. Under conditions allowing the complementary anti-sense nucleotide sequence to hybridize to the polypeptide mRNA, the amount of polypeptide translated is thus reduced or eliminated.

It is preferred that the cell to be modified in accordance with the methods of the present invention is of microbial origin, for example, a *Bacillus* strain which is suitable for the production of desired protein products, either homologous or heterologous to the cell.

30 The present invention further relates to a mutant cell of a parent cell which comprises a disruption or deletion of a nucleic acid sequence encoding the polypeptide or a control sequence thereof, which results in the mutant cell producing less of the polypeptide than the parent cell.

The polypeptide-deficient mutant cells so created are particularly useful as host cells for the expression of homologous and/or heterologous polypeptides. Therefore, the present invention further relates to methods for producing a homologous or heterologous polypeptide comprising (a) culturing the mutant cell under conditions suitable for production of the

polypeptide; and (b) recovering the polypeptide. In the present context, the term "heterologous polypeptides" is defined herein as polypeptides which are not native to the host cell, a native protein in which modifications have been made to alter the native sequence, or a native protein whose expression is quantitatively altered as a result of a manipulation of the host cell by recombinant DNA techniques.

In a still further aspect, the present invention relates to a method for producing a protein product essentially free of protease activity by fermentation of a cell which produces both a polypeptide encoded by a nucleic acid sequence of the present invention as well as the protein product of interest. The method comprises adding an effective amount of an agent capable of inhibiting protease activity to the fermentation broth either during or after the fermentation has been completed, recovering the product of interest from the fermentation broth, and optionally subjecting the recovered product to further purification. This method is further illustrated in the examples below.

In a still further alternative aspect, the present invention relates to a method for producing a protein product essentially free of protease activity, wherein the protein product of interest is encoded by a DNA sequence present in a cell which also contains a nucleic acid sequence of the present invention encoding the polypeptide having protease activity. The method comprises cultivating the cell under conditions permitting the expression of the product, subjecting the resultant culture broth to a combined pH and temperature treatment so as to reduce the protease activity substantially, and recovering the product from the culture broth. Alternatively, the combined pH and temperature treatment may be performed on an enzyme preparation recovered from the culture broth. The combined pH and temperature treatment may optionally be used in combination with a treatment with a protease inhibitor.

In accordance with this aspect of the invention, it is possible to remove at least 60%, preferably at least 75%, more preferably at least 85%, still more preferably at least 95%, and most preferably at least 99% of the protease activity. It is contemplated that a complete removal of protease activity may be obtained by use of this method.

The combined pH and temperature treatment is preferably carried out at a pH in the range of 6.5-7 and a temperature in the range of 25-70°C for a sufficient period of time to attain the desired effect, typically about 30 to 60 minutes.

The methods used for cultivation and purification of the product of interest may be performed by methods known in the art.

The methods of the present invention for producing an essentially protease-free product is of particular interest in the production of prokaryotic polypeptides, in particular *Bacillus* proteins such as enzymes. The enzyme may be selected from, e.g., an amylolytic enzyme, lipolytic enzyme, a proteolytic enzyme, a cellulytic enzyme, an oxidoreductase or a plant cell-

wall degrading enzyme. Examples of such enzymes include an aminopeptidase, amylase, amyloglucosidase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, galactosidase, beta-galactosidase, glucoamylase, glucose oxidase, glucosidase, haloperoxidase, hemicellulase, invertase, isomerase, laccase, ligase, lipase, lyase, mannosidase, oxidase, pectinolytic enzyme, peroxidase, phytase, phenoloxidase, polyphenoloxidase, proteolytic enzyme, ribonuclease, a transferase, transglutaminase, or xylanase. The protease-deficient cells may also be used to express heterologous proteins of pharmaceutical interest.

It will be understood that the term "prokaryotic polypeptides" includes not only native polypeptides, but also those polypeptides, *e.g.*, enzymes, which have been modified by amino acid substitutions, deletions or additions, or other such modifications to enhance activity, thermostability, pH tolerance and the like.

In a further aspect, the present invention relates to a protein product essentially free from protease activity which is produced by a method of the present invention.

15

Uses

The recombinant polypeptides encoded by the nucleic acid sequences of the present invention may be used in conventional applications of proteolytic enzymes, particularly at a high pH, *e.g.*, in laundry and dishwashing detergents, institutional and industrial cleaning, and leather processing. The recombinant polypeptides are particularly useful in detergents because of their enhanced stability toward oxidation under alkaline conditions, *e.g.*, bleaching agents of the peroxy type.

The recombinant polypeptides may also be used in numerous other applications including debittering or enhancing the degree of hydrolysis of protein hydrolysates, flavor development through hydrolysis of a protein, degradation of undesirable peptides, and enzymatic synthesis of peptides. The use of proteases in these and other applications are well established in the art.

The present invention is further described by the following examples which should not be construed as limiting the scope of the invention.

30

Examples

All primers and oligos were synthesized on an Applied Biosystems Model 394 Synthesizer (Applied Biosystems, Inc., Foster City, CA) according to the manufacturer's instructions.

35

Example 1: Construction of *Bacillus subtilis* donor strain BW154

Several genes (*spoIIAC*, *aprE*, *nprE*, *amyE*, and *srfC*) were deleted in the *Bacillus subtilis* A164 (ATCC 6051A) and 1630 (NCFB 736) host strains described herein. In order to
5 accomplish this task, plasmids containing deleted versions of these genes were introduced into these strains using the pLS20-mediated conjugation system (Koehler and Thorne, 1987, *supra*). Briefly, this system is comprised of a *Bacillus subtilis* "donor" strain which contains a large plasmid designated pLS20. pLS20 encodes the functions necessary for mobilizing pLS20 into a "recipient" strain of *Bacillus subtilis*. In addition, it has been shown that plasmids such as
10 pUB110 and pBC16 are also mobilized by this conjugation system (in the presence of pLS20). These plasmids contain a *cis*-acting region (*oriT*) and a gene (*orf-beta*) encoding a *trans*-acting function that acts at the *oriT* site and facilitates the mobilization of these plasmids into a recipient strain. Plasmids containing only *oriT* can also be mobilized if the donor strain contains both pLS20 and either pUB110 or pBC16 (in this case, *orf-beta* function is provided in
15 *trans*).

The pLS20 plasmid or a derivative such as pXO503 (Koehler and Thorne, 1987, *supra*) must be present in order for a strain to be a proficient donor. In addition, it is also desirable to have a means of counter-selecting against the donor strain after the conjugation has been completed. A counter-selection scheme has been developed that is very "clean" (no
20 background) and easy to implement. This involves introducing a deletion in the *dal* gene of the donor strain (encodes the D-alanine racemase enzyme which is required for cell wall synthesis) and selecting against the donor strain by growing the cell mixture from a conjugation experiment on solid media devoid of D-alanine (this amino acid must be added exogenously to the media in order for a *dal*- strain of *Bacillus subtilis* to grow).

In order to delete the genes mentioned above, pE194 replicons (erythromycin resistance) (Gryczan *et al.*, 1982, *Journal of Bacteriology* 152: 722-735) containing deleted versions of the genes and the *oriT* sequence had to be mobilized into the *Bacillus subtilis* A164 and A1630 strains. A suitable donor strain should have the following characteristics: 1) a deletion in the *dal* gene (for counter-selection) and 2) it must also contain pLS20 (pXO503
30 would be unsuitable in this case since the pE194 replicons must be maintained by erythromycin selection and pXO503 already confers resistance to this antibiotic) and either pUB110 or pBC16 to supply *orf-beta* function in *trans*. A description of how *Bacillus subtilis* BW154 was constructed as a donor strain follows.

(A) Introduction of a *dal* deletion in *Bacillus subtilis* to yield *Bacillus subtilis* BW96.

First, a strain of *Bacillus subtilis* with a mutation in the *bac-1* gene (this mutation abolishes the ability of the strain to synthesize the dipeptide antibiotic bacilysin) was chosen because wild-type *Bacillus subtilis* cells actually kill other species of *Bacillus* during the conjugation process and this killing potential is greatly reduced in cells which are *bac-1*.

5 Therefore, all donor strains have been constructed in a *bac-1* background.

The first step in constructing a suitable donor strain was to delete a portion of the *dal* gene in the *Bacillus subtilis* strain 1A758 which is *bac-1* (Bacillus Stock Center, Columbus, OH). A deleted version of the *dal* gene was constructed *in vitro* which could be exchanged for the wild-type *dal* gene on the bacterial chromosome. The 5' and 3' portions of the *dal* gene
10 were PCR-amplified using primers 1 and 2 to amplify the 5' portion of the gene (nucleotides 19-419, the A of the ATG codon is +1) and primers 3 and 4 to amplify the 3' portion of the gene (nucleotides 618-1037).

Primer 1: 5'-GAGCTCACAGAGATACGTGGGC-3' (SEQ ID NO:1)

Primer 2: 5'-GGATCCCACACCAAGTCTGTTCAT-3' (SEQ ID NO:2) (*Bam*HI site
15 underlined)

Primer 3: 5'-GGATCCGCTGGACTCCGGCTG-3' (SEQ ID NO:3) (*Bam*HI site underlined)

Primer 4: 5'-AAGCTTATCTCATCCATGGAAA-3' (SEQ ID NO:4) (*Hind*III site underlined)

The amplification reactions (100 µl) contained the following components: 200 ng of *Bacillus subtilis* 168 chromosomal DNA, 0.5 µM of each primer, 200 µM each of dATP,
20 dCTP, dGTP, and dTTP, 1x *Taq* polymerase buffer, and 1 U of *Taq* DNA polymerase. *Bacillus subtilis* 168 chromosomal DNA was obtained according to the procedure of Pitcher *et al.*, 1989, *Letters in Applied Microbiology* 8: 151-156. The reactions were performed under the following conditions: 95°C for 3 minutes, then 30 cycles each at 95°C for 1 minute, 50°C for 1 minute, and 72°C for 1 minute, followed by 5 minutes at 72°C. Reactions products were analyzed by
25 agarose gel electrophoresis. Both the 5' and 3' PCR products were cloned into the pCRII vector of the TA Cloning Kit (Invitrogen, San Diego, CA) according to the manufacturer's instructions. A pCRII clone was identified which contained the 5' half of the *dal* gene in an orientation such that the *Bam*HI site introduced by the PCR primer was adjacent to the *Bam*HI site of the pCRII polylinker (the other orientation would place the *Bam*HI sites much farther
30 apart). The pCRII clone containing the 3' half of the *dal* gene was then digested with *Bam*HI and *Hind*III and the *dal* gene fragment was then cloned into the *Bam*HI-*Hind*III site of the aforementioned pCRII clone containing the 5' half of the *dal* gene. This generated a pCRII vector containing the *dal* gene with a ~200 bp deletion in the middle flanked by a *Not*I site at

the 5' end (part of the pCRII polylinker) and a *Hind*III site at the 3' end of the gene.

In order to introduce this *dal* deletion into the bacterial chromosome, the deleted gene was cloned into the temperature-sensitive *Bacillus subtilis* replicon pE194 (Gryczan *et al.*, 1982, *supra*). The deleted *dal* gene was then introduced into the chromosome in two steps: first
5 by integrating the plasmid via homologous recombination into the chromosomal *dal* locus, followed by the subsequent removal of the plasmid (again via homologous recombination), leaving behind the deleted version of the *dal* gene on the bacterial chromosome. This was accomplished as follows: the deleted *dal* gene fragment (described above) was cloned into the *Not*I-*Hind*III site of the temperature sensitive plasmid pSK⁺/pE194 (essentially replacing the
10 pSK⁺ vector sequences with the *dal*Δ fragment). Plasmid pSK⁺/pE194 was constructed as follows: both Bluescript SK⁺ (Stratagene, La Jolla, CA) and pE194 were digested with *Xba*I. The pSK⁺ vector was then treated with calf intestinal alkaline phosphatase and the two plasmids were ligated together. The ligation mix was used to transform the *E. coli* strain DH5α and transformants were selected on LB plates containing ampicillin (100 μg/ml) and X-gal (5-
15 bromo-4-chloro-3-indolyl-β-D-galactopyranoside). Plasmid was purified from several "white" colonies and a chimera consisting of both pE194 and pSK⁺ was identified by restriction enzyme digestion followed by gel electrophoresis. This plasmid was digested with *Hind*III and *Not*I. The fragment comprising the pE194 replicon was then gel-purified and ligated with gel-purified *dal*Δ gene fragment (*Hind*III-*Not*I). The ligation mix was used to transform the *bac*-1 strain
20 *Bacillus subtilis* 1A758 (Bacillus Stock Center, Columbus, OH), and transformants were selected on Tryptone blood agar base (TBAB) plus erythromycin (5 μg/ml) plates and grown at the permissive temperature of 34°C. Plasmid DNA was purified from five erythromycin resistant transformants and analyzed by restriction enzyme digestion/gel electrophoresis. A plasmid was identified which corresponded to pE194 containing the *dal*-deleted fragment. The
25 strain harboring this plasmid was subsequently used for the introduction of the *dal* deletion into the chromosome via homologous recombination.

In order to obtain the first cross-over (integration of the *dal* deletion plasmid into the *dal* gene on the chromosome), the transformed strain was streaked onto a TBAB plate containing D-alanine (0.1 mg/ml) and erythromycin (5 μg/ml) and grown overnight at the non-permissive
30 temperature of 45°C. A large colony was restreaked under the same conditions yielding a homogeneous population of cells containing the temperature-sensitive plasmid integrated into the *dal* gene on the chromosome. At the non-permissive temperature, only cells which contained the plasmid in the chromosome were capable of growing on erythromycin since the

plasmid was incapable of replicating. In order to obtain the second cross-over event (resulting in excision of the plasmid from the chromosome leaving behind the deleted version of the *dal* gene), a loopful of cells was transferred to 20 ml of Luria broth supplemented with D-alanine (0.1 mg/ml) and grown to late log phase without selection at the permissive temperature of 34°C to permit function of the origin of replication and occurrence of the second cross-over event. Cells were transferred 4 times more (1/100 dilution each transfer) to allow the plasmid to excise from the chromosome and segregate out of the population. Finally, cells were plated for single colonies at 34°C on TBAB plates supplemented with D-alanine (0.1 mg/ml) and replica-plated onto TBAB plates without D-alanine (0.1 mg/ml) and TBAB plates with D-alanine (0.1 mg/ml) and erythromycin (5 µg/ml) to score colonies which were *dal*- and *erm*^s. Two out of 50 colonies yielded this phenotype. The resulting strain was designated *Bacillus subtilis* BW96, a *bac-1*, *dal*- strain.

(B) Introduction of pLS20 and pBC16 into the *bac-1*, *dal*-deleted *Bacillus subtilis* strain to yield the conjugation proficient donor strain *Bacillus subtilis* BW154.

A donor strain was chosen for introducing plasmids pLS20 and pBC16 into *Bacillus subtilis* BW96 wherein the donor strain is an erythromycin sensitive *Bacillus subtilis* strain (in order to provide a counter-selection against the donor strain) which contains both pLS20 and pBC16. A *dal*-deleted *Bacillus subtilis* strain containing pLS20 and pBC16 was chosen as a suitable donor strain which was constructed as follows: *Bacillus subtilis* DN1686 (U.S. Patent No. 4,920,048) was transformed with pHV1248 (Petit *et al.*, 1990, *Journal of Bacteriology* 172: 6736-6740) to make cells erythromycin resistant. The conjugative element pLS20 was transferred to the *Bacillus subtilis* DN1686 (pHV1248) strain along with pBC16 by conjugation with *Bacillus subtilis* (*natto*) 3335 UM8 (Koehler and Thorne, 1987, *supra*). The transconjugants were selected as tetracycline and erythromycin resistant colonies possessing a *dal* deletion. Colonies carrying pLS20 were scored by their ability to transfer pBC16 to other *Bacillus subtilis* strains by conjugation. Finally the conjugative strain was cured of pHV1248 by raising the temperature to 50°C yielding the donor strain: *Bacillus subtilis* DN1686 containing pLS20 and pBC16.

In order to introduce these plasmids into *Bacillus subtilis* BW96, a suitable counter-selection scheme had to be implemented, and therefore, *Bacillus subtilis* BW96 was transformed with a temperature-sensitive plasmid pSK⁺/pE194 conferring erythromycin resistance which could be subsequently removed by growth at a non-permissive temperature. The pLS20 and pBC16 plasmids were mobilized from *Bacillus subtilis* DN1686 containing pLS20 and pBC16 into *Bacillus subtilis* BW96 (harboring pSK⁺/pE194) according to the

following procedure. A loopful of each cell type was mixed together on a TBAB plate supplemented with D-alanine (50 µg/ml) and incubated at 33°C for 5 hours. The cells were scraped from the plate and transferred to 1 ml of LB medium. The cells were spread at various dilutions onto TBAB plates supplemented with tetracycline (10 µg/ml), erythromycin (5 µg/ml), and D-alanine (50 µg/ml) and grown at 34°C to select for recipient cells which acquire pBC16 and in many cases pLS20 as well. To test whether pLS20 was also present in any of the transconjugants, ten colonies were tested for their ability to transfer pBC16 into *Bacillus subtilis* PL1801. *Bacillus subtilis* PL1801 is *Bacillus subtilis* 168 (Bacillus Stock Center, Columbus, OH) with deletions of the genes *apr* and *npr*). However, *Bacillus subtilis* 168 may also be used. Donors capable of mobilizing pBC16 must contain pLS20 as well. Once a conjugation proficient strain was identified (*Bacillus subtilis* *bac-1*, *dal-* containing pLS20 plus pBC16 plus pSK⁺/pE194), the pSK⁺/pE194 plasmid was cured from the strain by propagating the cells in LB medium supplemented with tetracycline (5 µg/ml) and D-alanine (50 µg/ml) overnight at 45°C, plating for single colonies at 33°C on TBAB plates supplemented with D-alanine (50 µg/ml), and identifying erythromycin sensitive colonies. This procedure yielded *Bacillus subtilis* BW154 which is *Bacillus subtilis* *bac-1*, *dal-* containing pLS20 and pBC16.

A summary of the *Bacillus* strains and plasmids is presented in Table 1.

Table 1: Bacterial strains and plasmids

Bacillus subtilis strains:

	<i>B. subtilis</i> (<i>natto</i>)	pLS20
	DN1686	<i>dal-</i>
	DN1280	<i>dal-</i>
	MT101	DN1280 (pXO503)
25	1A758	168 <i>bac-1</i> (Bacillus Stock Center, Columbus, Ohio)
	BW96	1A758 <i>dalΔ</i>
	BW97	1A758 <i>dalΔ::cat</i> (pXO503)
	BW99	1A758 <i>dalΔ</i> (pPL2541-tet)
	BW100	1A758 <i>dalDΔ</i> (pXO503), (pPL2541-tet)
30	PL1801	<i>aprΔ</i> , <i>nprΔ</i>

Plasmids:

pBC16	Mob ⁺ , Tc ^r
pE194	temperature sensitive

pLS20	Tra ⁺
pXO503	Tra ⁺ , MLS ^r (=pLS20::Tn917)
pPL2541-tet	Mob ⁺ , Tc ^r (pE194 ts ori)
pCAsub2	Mob ⁺ , Cm ^r , Ap ^r , (pE194 ts ori)
5 pSK ⁺ /pE194	Em ^r , Ap ^r , temperature-sensitive
pShv2	Tra ⁺ , Em ^r , Cm ^r , temperature-sensitive
pHV1248	Em ^r , temperature-sensitive

Tra⁺ implies that the plasmid confers upon any *Bacillus subtilis* strain bearing it the ability to conjugate, that is, the plasmid encodes all of the functions for mobilizing a conjugatable
10 plasmid from the donor to a recipient cell.

Mob⁺ implies that a plasmid is capable of being mobilized via conjugation by a strain which contains a Tra⁺ plasmid (pLS20 or pXO503). The plasmid must contain a *cis*-acting sequence and a gene encoding a trans-acting protein (*oriT* and *orf-beta*, respectively, in the case of
15 pBC16) or just an *oriT* sequence (in the case of pPL254-tet, here a plasmid supplying *orf-beta* functions in *trans* must also be present in the cell as well such as pBC16).

Example 2: Deletion of the *spoIIAC* gene of *Bacillus subtilis* A164 (ATCC 6051A)

A deleted version of the *spoIIAC* gene, which encodes sigma F permitting cells to
20 proceed through stage II of sporulation, was created by splicing by overlap extension (SOE) technique (Horton *et al.*, 1989, *Gene* 77: 61-68). *Bacillus subtilis* A164 (ATCC 6051A) chromosomal DNA was obtained by the method of Pitcher *et al.*, 1989, *supra*. Primers 5 and 6 shown below were synthesized for PCR amplification of a region from *Bacillus subtilis* A164 chromosomal DNA extending from 205 nucleotides upstream of the ATG start codon of the
25 *spoIIAC* gene to 209 nucleotides downstream of the ATG start. The underlined nucleotides of the upstream primer were added to create a *HindIII* site. The underlined nucleotides of the downstream primer were complementary to bases 507 to 524 downstream of the ATG translational start codon. Primers 7 and 8 were synthesized to PCR-amplify a region extending from 507 to 884 nucleotides downstream of the ATG translational start codon. The underlined
30 region of primer 7 was exactly complementary to the 3' half of primer 6 used to amplify the upstream fragment.

Primer 5: 5'-AAGCTTAGGCATTACAGATC-3' (SEQ ID NO:5)

Primer 6: 5'-CGGATCTCCGTCATTTTCCAGCCCGATGCAGCC-3' (SEQ ID NO:6)

35 Primer 7: 5'-GGCTGCATCGGGCTGGAAAATGACGGAGATCCG-3' (SEQ ID

NO:7)

Primer 8: 5'-GATCACATCTTTTCGGTGG-3' (SEQ ID NO:8)

The two sets of primers were used to amplify the upstream and downstream *spoIIAC* fragments in separate PCR amplifications. The amplification reactions (25 μ l) contained the following components: 200 ng of *Bacillus subtilis* A164 chromosomal DNA, 0.5 μ M of each primer, 200 μ M each of dATP, dCTP, dGTP, and dTTP, 1 x *Taq* polymerase buffer, and 0.625 U of *Taq* DNA polymerase. *Bacillus subtilis* A164 chromosomal DNA was obtained according to the procedure of Pitcher *et al.*, 1989, *supra*. The reactions were performed under the following conditions: 96°C for 3 minutes, then 30 cycles each at 96°C for 1 minute, 50°C for 1 minute, and 72°C for 1 minute, followed by 3 minutes at 72°C to insure addition of a terminal adenine residue to the amplified fragments (Invitrogen, San Diego, CA). Amplification of the expected products was verified by electrophoresis through a 1.5% agarose gel.

A new PCR mixture containing 2.5 μ l of each amplification reaction above was then performed under the same conditions but containing only primers 5 and 8, producing a "spliced" fragment of 1089 nucleotides, representing the *spoIIAC* gene lacking 298 internal nucleotides. This fragment was cloned into the pCRII vector using the Invitrogen TA Cloning Kit according to the manufacturer's instructions, excised as a *Hind*III-*Eco*RI fragment, and then cloned into *Hind*III/*Eco*RI-digested pShv2. pShv2 (Figure 1) is a shuttle vector constructed by ligating *Xba*I-cut pBCSK⁺ (Stratagene, La Jolla, CA) containing *oriT* of pUB110 with *Xba*I-cut pE194, followed by ligation of *oriT* from pUB110 as a PCR-amplified fragment containing *Sst*I compatible ends. The *oriT* fragment permits mobilization of the plasmid into *Bacillus subtilis* A164 by pLS20-mediated conjugation (Battisti *et al.*, 1985, *Journal of Bacteriology* 162: 543-550). pShv2- Δ *spoIIAC* was transformed into donor strain *Bacillus subtilis* BW154 (Example 1). *Bacillus subtilis* BW154 (pShv2- Δ *spoIIAC*) was used as a donor strain to introduce the shuttle vector containing the deleted gene into *Bacillus subtilis* A164.

Exchange of the deleted gene with the intact chromosomal gene was effected by conjugation of *Bacillus subtilis* BW154 transformed with pShv2- Δ *spoIIAC* with *Bacillus subtilis* A164, selection of erythromycin-resistant transconjugants, and growth at 45°C. At this temperature, the pE194 replicon is inactive, and cells are only able to maintain erythromycin resistance by Campbell integration of the plasmid containing the deleted gene at the *spoIIAC* locus. A second recombination event, resulting in loopout of vector DNA and replacement of the intact *spoIIAC* gene with the deleted gene, was effected by growth of the strain for two rounds in LB medium without antibiotic selection at 34°C, a temperature permissive for

function of the pE194 replicon. Colonies in which gene replacement had occurred were selected according to the following criteria: 1) absence of erythromycin (*erm*) resistance encoded by the shuttle vector pShv2, 2) decreased opacity on sporulation medium, indicating failure to sporulate, and 3) PCR amplification with primers 5 and 8 to obtain a fragment of 791 nucleotides instead of 1089 nucleotides representing the undeleted version of the gene.

Example 3: Deletion of the *nprE* gene of *Bacillus subtilis* A164 $\Delta spoIIAC$

An upstream portion of the neutral protease (*nprE*) gene (nucleotides 40-610 downstream of the GTG start codon) was PCR-amplified from *Bacillus subtilis* A164 $\Delta spoIIAC$ chromosomal DNA prepared in the manner described in Example 2 using primers 9 and 10 shown below. A downstream portion of the *nprE* gene (nucleotides 1040-1560) was PCR amplified using primers 11 and 12 shown below. Primers 10 and 11 were designed such that there would be a 15 base pair overlap between the two fragments (denoted by underlining). The amplification reactions (25 μ l) contained the same components and were performed under the same conditions specified in Example 2.

Primer 9: 5'-CGTTTATGAGTTTATCAATC-3' (SEQ ID NO:9)

Primer 10: 5'-AGACTTCCCAGTTTGCAGGT-3' (SEQ ID NO:10)

Primer 11: 5'-CAAAC TGGGAAGTCTCGACGGTTCATTCTTCTCTC-3' (SEQ ID NO:11)

Primer 12: 5'-TCCAACAGCATTCCAGGCTG-3' (SEQ ID NO:12)

The amplified upstream and downstream fragments were gel purified with the Qiaex II Kit according to the manufacturer's instructions (Qiagen, Chatsworth, CA). A new PCR mixture (100 μ l) containing approximately 20 ng of each purified fragment was performed. The SOE reaction was performed under the following conditions: cycles 1-3 in the absence of primers to generate a "spliced" fragment, and cycles 4-30 in the presence of primers 9 and 12 under the conditions specified in Example 2. The amplified SOE fragment was cloned into the pCRII vector and verified by restriction analysis. The fragment was then cloned into pShv2 as a *Bam*HI-*Xho*I fragment. This plasmid, pShv2- $\Delta nprE$, was transformed into *Bacillus subtilis* BW154 to generate a suitable donor strain for conjugation. The plasmid was then mobilized into *Bacillus subtilis* A164 $\Delta spoIIAC$. The $\Delta nprE$ gene was introduced into the chromosome of *Bacillus subtilis* A164 $\Delta spoIIAC$ by temperature shift as described in Example 2. An *nprE*-phenotype was scored by patching *erm*^S colonies onto TBAB agar plates supplemented with 1% non-fat dry milk and incubating overnight at 37°C where a noticeably reduced clearing zone is observed. The 430 base pair deletion was verified by PCR analysis on chromosomal DNA using primers 9 and 12.

Example 4: Deletion of the *aprE* gene of *Bacillus subtilis* A164 $\Delta spoIIAC \Delta nprE$

SOE was used to create a deleted version of the *Bacillus subtilis aprE* gene which encodes an alkaline subtilisin protease. An upstream portion of *aprE* was PCR amplified using
 5 primers 13 and 14 shown below from *Bacillus subtilis* A164 chromosomal DNA prepared as described in Example 2 to create a fragment extending from 189 nucleotides upstream of the translational start codon to 328 nucleotides downstream of the start. The underlined nucleotides of primer 13 were included to add an *EcoRI* site. The underlined nucleotides of primer 14 were added to provide complementarity to the downstream PCR fragment and to add a *SalI* site. A
 10 downstream portion of the *aprE* gene was PCR-amplified using primers 15 and 16 to create a fragment extending from 789 nucleotides to 1306 nucleotides downstream of the *aprE* translational start codon. Underlined regions of primers 14 and 15 were added to provide complementarity between the upstream and downstream fragments. The underlined nucleotides of primer 16 were included to add a *HindIII* site. The amplification reactions (25 μ l) contained
 15 the same components and were conducted under the same conditions as described in Example 2.

Primer 13: 5'-GCGAATTCTACCTAAATAGAGATAAAATC-3' (SEQ ID NO:13)

Primer 14: 5'-GTTTACCGCACCTACGTCGACCCTGTGTAGCCTTGA-3' (SEQ ID NO:14)

20 Primer 15: 5'-TCAAGGCTACACAGGGTCGACGTAGGTGCGGTAAAC-3' (SEQ ID NO:15)

Primer 16: 5'-GCAAGCTTGACAGAGAACAGAGAAGCCAG-3' (SEQ ID NO:16)

The amplified upstream and downstream fragments were purified using the Qiaquick PCR Purification Kit according to the manufacturer's instructions (Qiagen, Chatsworth, CA).
 25 The two purified fragments were then spliced together using primers 13 and 16. The amplification reaction (50 μ l) contained the same components as above except the chromosomal DNA was replaced with 2 μ l each of the upstream and downstream PCR products. The reactions were incubated for 1 cycle at 96°C for 3 minutes (without the dNTPs and *Taq* polymerase), and then for 30 cycles each at 96°C for 1 minute and 72°C for 1 minute
 30 resulting in a deleted version of *aprE* lacking 460 nucleotides from the coding region. The reaction product was isolated by agarose electrophoresis, cloned into pCRII, excised as an *EcoRI-HindIII* fragment, and then cloned into *EcoRI/HindIII*-digested pShv2 to yield pShv2- $\Delta aprE$. This plasmid was introduced into the donor strain described above for conjugal transfer into *Bacillus subtilis* A164 $\Delta spoIIAC \Delta nprE$.

Replacement of *aprE* with the deleted gene was effected as described above for *spoIIAC* and *nprE*. Colonies in which *aprE* had been deleted were selected by erythromycin sensitivity and reduced clearing zones on agar plates with an overlay containing 1% non-fat dry milk. Deletion of *aprE* was confirmed by PCR.

5 *Bacillus subtilis* A164 Δ *spoIIAC* Δ *nprE* Δ *aprE* is herein designated *Bacillus subtilis* A164 Δ 3.

Example 5: Deletion of the *amyE* gene of *Bacillus subtilis* A164 Δ *spoIIAC* Δ *nprE* Δ *aprE*

SOE was used to create a deleted version of the *amyE* gene which encodes *Bacillus*
10 *subtilis* alpha-amylase. An upstream portion of *amyE* was PCR-amplified from *Bacillus subtilis* A164 chromosomal DNA using primers 17 and 18 shown below. This created a fragment extending from 421 nucleotides upstream of the *amyE* translational start codon to nucleotide 77 of the *amyE* coding sequence, adding a *SalI* site at the upstream end and *SfiI* and *NotI* sites at the downstream end. A downstream portion of *amyE* was PCR-amplified using
15 primers 19 and 20 shown below. This created a fragment extending from nucleotide 445 to nucleotide 953 of the *amyE* coding sequence, and added *SfiI* and *NotI* sites at the upstream end and a *HindIII* site at the downstream end. Restriction sites are denoted by underlining. The amplification reactions (25 μ l) contained the same components and were conducted under the same conditions as described in Example 2.

20 The two fragments were then spliced together by PCR using primers 17 and 20. The amplification reaction (25 μ l) contained the same components as above except the chromosomal DNA was replaced with 2 μ l each of the upstream and downstream PCR products. The reactions were incubated for 1 cycle at 96°C for 3 minutes (without the dNTPs and *Taq* polymerase), and then for 30 cycles each at 96°C for 1 minute and 72°C for 1 minute.
25 This reaction fused the two fragments by overlap at the region of complementarity between the two (the *SfiI* and *NotI* sites) and resulted in a fragment of *amyE* lacking 367 nucleotides from the coding region and having an *SfiI* site and a *NotI* site incorporated between the two portions of *amyE*. The reaction product was isolated by electrophoresis using a 1% agarose gel according to standard methods. This fragment was cloned into pCRII according to the
30 manufacturer's instructions to yield pCRII- Δ *amyE*.

Primer 17: 5'-CGTCGACGCCTTTGCGGTAGTGGTGCTT-3' (SEQ ID NO:17) (*SalI* site underlined)

Primer 18: 5'-CGCGGCCGCAGGCCCTTAAGGCCAGAACCAAATGAA-3' (SEQ

ID NO:18) (*NotI* and *SfiI* sites underlined)

Primer 19: 5'-TGGCCTTAAGGGCCTGCGGCCGCGATTTCCAATG-3' (SEQ ID NO:19) (*SfiI* and *NotI* sites underlined)

Primer 20: 5'-GAAGCTTCTTCATCATCATTGGCATACG-3' (SEQ ID NO:20)
5 (*HindIII* site underlined)

pShv2.1 was created by digesting pShv2 with *NotI*, filling in the cohesive ends with Klenow fragment and dNTPs, and religating the plasmid. This procedure destroyed the *NotI* recognition site of pShv2. The deleted *amyE* fragment was excised from pCRII- Δ *amyE* as a *SalI*-*HindIII* fragment and cloned into *SalI*/*HindIII*-digested pShv2.1 to yield pShv2.1- Δ *amyE*.

10 This plasmid was introduced into *Bacillus subtilis* BW154 for conjugal transfer into *Bacillus subtilis* A164 Δ *spoIIAC* Δ *nprE* Δ *aprE*.

Replacement of *amyE* with the deleted gene was effected as described above for *spoIIAC*, *nprE*, and *aprE*. Colonies in which gene replacement had occurred were selected by erythromycin sensitivity and the inability to produce a zone of clearing on starch azure overlay
15 plates. Deletion of *amyE* was confirmed by PCR amplification of the deleted gene from chromosomal DNA using primers 17 and 20.

Example 6: Deletion of the *srfC* gene of *Bacillus subtilis* A164 Δ *spoIIAC* Δ *nprE* Δ *aprE* Δ *amyE* to produce *Bacillus subtilis* A164 Δ *spoIIAC* Δ *nprE* Δ *aprE* Δ *amyE* Δ *srfC*

20 Primers 21-24 shown below were synthesized for the creation of a deletion in *srfC* of the surfactin operon. Primer 21 overlaps an existing *HindIII* site (underlined) in the *srfC* gene, and in conjunction with primer 22 permits PCR amplification of a region extending from 410 nucleotides to 848 nucleotides downstream of the translational start of *srfC*. The underlined portion of primer 22 is complementary to nucleotides 1709-1725 downstream of the ATG start
25 codon. Primers 23 and 24 permit PCR amplification of a region of 1709 to 2212 nucleotides downstream of the translational start of *srfC*. The underlined portion of primer 23 is complementary to nucleotides 835-848 downstream of the ATG codon. The amplification reactions (25 μ l) contained the same components and were performed under the same conditions as described in Example 2.

30 Primer 21: 5'-AAGCTTTGAATGGGTGTGG-3' (SEQ ID NO:21)

Primer 22: 5'-CCGCTTGTTCTTTCATCCCCTGAAACAACTGTACCG-3' (SEQ ID NO:22)

Primer 23: 5'-CAGTTGTTTCAGGGGATGAAAGAACAAGCGGCTG-3' (SEQ ID

NO:23)

Primer 24: 5'-CTGACATGAGGCACTGAC-3' (SEQ ID NO:24)

Primers and other contaminants were removed from the PCR products with a Qiagen PCR spin column (Qiagen, Chatsworth, CA). The complementarity between the two PCR-generated fragments permitted splicing by SOE. The PCR products (2 µl or approximately 50 ng each) were spliced together under the same PCR conditions as described above with the "outside primers", primers 21 and 24, except that the first 3 cycles were performed before addition of the primers to extend the overlapping regions. The SOE reaction resulted in a 955 nucleotide fragment that lacked an internal 859 nucleotides of the *srfC* gene. The deleted portion represents the region of *srfC* responsible for addition of the seventh amino acid leucine to the surfactin molecule, and furthermore results in a frameshift mutation which results in termination of the peptide prior to the thioesterase active site-like region, presumed to be involved in surfactin release from the SrfC protein (Cosmina *et al.*, 1993, *supra*).

Replacement of *srfC* with the deleted gene was effected as described above for *spoIIAC*, *nprE*, and *aprE*, and *amyE*. Colonies in which gene replacement had occurred were selected by erythromycin sensitivity, the inability to produce a zone of clearing on blood agar plates (Grossman *et al.*, 1993, *Journal of Bacteriology* 175: 6203-6211), and lack of foaming upon cultivation for 4 days at 37°C and 250 rpm in 250 ml shake flasks containing 50 ml of PS-1 medium composed of 10% sucrose, 4% soybean flour, 0.42% anhydrous disodium phosphate, and 0.5% calcium carbonate supplemented with 5 µg of chloramphenicol per ml. Deletion of *srfC* was confirmed by PCR amplification of the deleted gene from chromosomal DNA using primers 21 and 24.

Bacillus subtilis A164 $\Delta spoIIAC \Delta nprE \Delta aprE \Delta amyE \Delta srfC$ is herein designated *Bacillus subtilis* A164 $\Delta 5$.

25

Example 7: Construction of *Bacillus subtilis* A1630 $\Delta spoIIAC \Delta nprE \Delta aprE \Delta amyE \Delta srfC$

Bacillus subtilis A1630 $\Delta spoIIAC \Delta nprE \Delta aprE \Delta amyE \Delta srfC$ was constructed from *Bacillus subtilis* A1630 (NCFB 736, formerly NCDO 736) according to the same procedures described in Examples 1-6 for *Bacillus subtilis* A164 $\Delta spoIIAC \Delta nprE \Delta aprE \Delta amyE \Delta srfC$ (*Bacillus subtilis* A164 $\Delta 5$), using the deletion plasmids constructed for the *Bacillus subtilis* A164 deletions.

30

Bacillus subtilis A1630 $\Delta spoIIAC \Delta npr \Delta apr \Delta amyE \Delta srfC$ is herein designated *Bacillus subtilis* A1630 $\Delta 5$.

Example 8: Preparation of chromosomal DNA of *Bacillus* JP170

Bacillus JP170 (NCIB 12513) was grown overnight at 37°C in 50 ml of Luria-Bertani (LB) broth containing 0.1 M NaHCO₃ pH 8. Genomic DNA was prepared according to the method of Pitcher *et al.*, 1989, *supra*.

5

Example 9: Preparation of probes of the *Bacillus* JP170 protease gene

Based on the N-terminal and internal amino acid sequences of the *Bacillus* JP170 protease (JP 4197182) shown below, primers were synthesized to clone the *Bacillus* JP170 protease gene:

10 N-terminus: NDVARGIVKADVAQNNFGLYGQGQIVADTGLDTGRNDS (SEQ ID NO:25)
Internal peptide: GAADVGLGFPNGNQGWGRVTLDK (SEQ ID NO:26)

The primers designated 170-291, 1701, and 1702B shown below (where I=inosine) were used in the amplification reactions described below.

170-291: 5'-CCCCAICCITGITTICCTTIGGIAAICC-3' (SEQ ID NO:27)

15 1701: 5'-GGIATIGTIAAIGCIGAIGTIGCICAIAAIAAITTIGG-3' (SEQ ID NO:28)

1702B: 5'-TAIGGICAIGGICAIATIGTIGCIGTIGCIGAIACIGG-3' (SEQ ID NO:29)

Amplification reactions were prepared with 50 pmol of either primers 1701 and 170-291 or 1702B and 170-291, 7 µg of *Bacillus* JP170 chromosomal DNA as template, 1X PCR buffer (Perkin-Elmer, Foster City, CA), 100 µM each of dATP, dCTP, dGTP, and dTTP, and
20 0.5 U of AmpliTaq Gold (Perkin-Elmer, Foster City, CA). Reactions were incubated in a Stratagene Robocycler 40 (Stratagene, La Jolla, CA) programmed for 1 cycle at 96°C for 3 minutes and 30 cycles each at 40°C for 1 minute, 40°C for 1 minute, and 72°C for 1 minute.

Amplification with primers 170-291 and 1701 resulted in a 905 bp product designated 1/291, and with primers 1702B and 170-291 an 863 bp product designated 2B/291. Both PCR
25 products were individually cloned into the Invitrogen TA Cloning Kit vector pCR2.1 (Invitrogen, San Diego, CA) according to the manufacturer's instructions. Sequencing with an Applied Biosystems Model 377 Sequencer (Applied Biosystems, Foster City, CA) showed that these PCR products had 90% identity to the amino acid sequence of the Ya protease disclosed in JP 4197182 based on alignment of the deduced amino acid sequences in the GeneAssist
30 1.1b4 database (Applied Biosystems, Foster City, CA). The amino acid sequence of the PCR product also had a 35% identity to the amino acid sequence of the *Bacillus* serine protease subtilisin.

Primers 170-291, 1701, and 1702B were then used to PCR-amplify DIG-labeled probes of 1/291 and 2B/291 using the Genius System PCR DIG Probe Synthesis Kit (Boehringer
35 Mannheim Corporation, Indianapolis, IN) according to the manufacturer's under the same PCR

conditions as described above.

Example 10: Screening of chromosomal libraries

Probe 2B/291 described in Example 9 was used to screen a chromosomal library of
5 *Bacillus* JP170. The library was constructed by ligating *Sau*3A partially-digested (4-8 kb)
Bacillus JP170 chromosomal DNA into the *Bam*HI sites of the vector pSJ1678 (Figure 2).
Escherichia coli DH5 α (Gibco BRL, Gaithersburg, MD) was transformed with the
chromosomal library and screened by colony lifts using the DIG-labeled probe 2B/291
following the Genius System instructions. After screening approximately 4600 colonies, 1
10 colony hybridized to the probe and was designated Clone 1. Plasmid DNA from Clone 1 was
prepared using a QIAprep 8 Plasmid Kit (Qiagen, Chatsworth, CA). Restriction digests of
plasmid DNA indicated that Clone 1 contained an insert of approximately 13 kb.

DNA from Clone 1 and *Bacillus* JP170 chromosomal DNA were analyzed by Southern
hybridization using 2B/291 as a probe. Specifically, 7 μ g of *Bacillus* JP170 chromosomal
15 DNA and 16 ng of Clone 1 plasmid DNA was digested with *Eco*RI and *Hind*III and the digests
were electrophoresed on a 1% agarose gel. The DNA was capillary transferred onto a Nytran
Plus membrane (Schleicher and Schuell, Keene, NH) following the manufacturer's instructions.
The membrane was then probed following the Genius System instructions.

The Southern hybridization results demonstrated that the 2B/291 probe hybridized with
20 2 bands of 1800 and 1400 bp from the *Eco*RI digested chromosomal DNA and with 2 bands of
approximately 2000 and 1800 bp from the *Eco*RI digested Clone 1 DNA. The 2B/291 probe
also hybridized with 2 bands of 2000 and 1800 bp from the *Hind*III digested chromosomal
DNA and with 1 band of approximately 2000 bp from the *Hind*III digested Clone 1 DNA.
These results indicated that Clone 1 did not contain the entire gene since only the single 2000
25 bp band hybridized with the 2B/291 probe. Sequencing of the *Hind*III fragment from Clone 1
suggested it contained a partial open reading frame which contained 1200 bp of the 5' end of
the protease gene, based on homology to the protease disclosed in JP 4197182.

Since the Southern hybridization results indicated that the 3' end was located on an
1800 bp *Hind*III fragment, a new library was constructed. *Bacillus* JP170 chromosomal DNA
30 was digested with *Hind*III and the digest electrophoresed on a 1% agarose gel. Fragments
ranging in size from 1500 bp to 2200 bp were excised and purified using a QIAquick Gel
Extraction Kit (Qiagen, Chatsworth, CA). These fragments were then ligated into the *Hind*III
site of pUC118. *E. coli* DH5 α (Gibco BRL, Gaithersburg, MD) was transformed with the
ligation following the manufacturer's instructions and transformants were screened using the
35 2B/291 probe as described above. After screening 3200 transformants, 5 positive transformants

were identified. Plasmid DNA from each of the 5 transformants was prepared using a QIAprep 8 Plasmid Kit according to the manufacturer's instructions and digested with *HindIII*. The resulting restriction fragments were compared to Clone 1 plasmid DNA restriction fragments by gel electrophoresis. All 5 clones contained fragments identical in size to the previously cloned 5' end of the *Bacillus* JP170 protease gene.

Example 11: Isolation of the 3' end of the *Bacillus* JP170 protease gene by inverse PCR

Inverse PCR was used to isolate the 3' end of the *Bacillus* JP170 protease gene by amplifying the region downstream of the chromosomal clone isolated in the library screen (Clone 1) described in Example 10. Southern hybridization of chromosomal DNA showed that the 3' end of the gene should be contained on an 1800 bp *EcoRI* fragment (Example 10). Size-selected chromosomal DNA was prepared by digestion of the *Bacillus* JP170 chromosomal DNA with *EcoRI* followed by electrophoresis on a 1% agarose gel. Fragments ranging from approximately 1600 bp to 2000 bp were isolated using a QIAquick Gel Extraction Kit and eluted in 30 µl of TE. The *EcoRI* fragments were self-ligated in a 10 µl ligation reaction containing the following components: 1 µl of size-selected DNA, 1x ligation buffer (Boehringer Mannheim, Indianapolis, IN), and 1 unit of T4 DNA Ligase (Boehringer Mannheim, Indianapolis, IN). The ligation was incubated overnight at 14°C. A 3 µl volume of the ligation mix was then digested with *HindIII* in a 20 µl reaction to linearize the self-ligated *EcoRI* fragments between the binding sites of the PCR primers. This linearized DNA was then used as a template in a PCR reaction with 2 divergent primers 17011 and 17012, whose sequences shown below were based on the sequence of the protease gene contained on Clone 1.

17011: 5'-GTAGGTTTTTCGGTTGCCCCAACTGTAATCGC-3' (SEQ ID NO:30)

17012: 5'-GGTCCTACTAGAGATGGACGTATTAAGCCGG-3' (SEQ ID NO:31)

The amplification was performed using the GeneAmp Kit (Perkin-Elmer, Foster City, CA) following the manufacturer's instructions.

The amplification resulted in a 1700 bp PCR product. The 1700 bp product was cloned into pCR2.1 from the TA Cloning Kit and sequenced as previously described. Comparison of the deduced amino acid sequence with the known amino acid sequence of the protease disclosed in JP 4197182 indicated that the cloned inverse PCR product contained the 3' end of the *Bacillus* JP170 protease gene.

Example 12: Reconstruction of the *Bacillus* JP170 protease gene

The 5' and 3' ends of the *Bacillus* JP170 protease gene were cloned into the multicopy *Bacillus* vector pSJ2882-MCS (Figure 3) to reconstruct the *Bacillus* JP170 protease gene.

pSJ2882-MCS is derived from pHP13 (Haima *et al.*, 1987, *Molecular General Genetics* 209: 335-342), but contains a *SfiI*-*NotI*-flanked MCS, and also a *SstI* 0.5 kb fragment containing the *oriT* region from pUB110. This latter fragment permits mobilization of the plasmid into *Bacillus subtilis* A164 by pLS20-mediated conjugation (Battisti *et al.*, 1985, *Journal of Bacteriology* 162: 543-550).

PCR-amplification from *Bacillus* JP170 chromosomal DNA with primers adding new restriction sites allowed cloning of the 5' and 3' fragments separately into the plasmid. The following primers were used for the addition of a 5' *SmaI* site into the 5' *Bacillus* JP170 protease gene fragment:

170Sma: 5'-CTCCCCCGGGGATGTGTTATAAATTGAGAGGAG-3' (SEQ ID NO:32)
 17030R: 5'-CCTCGTGAAGAGAATTGAGCAACATGG-3' (SEQ ID NO:33)

The following primers were used for the addition of a 3' *NotI* site into the 3' *Bacillus* JP170 protease gene fragment:

17027F: 5'-GCGATTACAGTTGGGGCAACC-3' (SEQ ID NO:34)
 17035NOT: 5'-GCGGCCGCGTACTCTCATCAATTTCCCAAGC-3' (SEQ ID NO:35)
 17036NOT: 5'-GCGGCCGCGTCATAAACGTTGCAATCGTGCTC-3' (SEQ ID NO:36)

The amplification reactions were performed under the same conditions as described in Example 9.

The 5' end PCR product included a new *SmaI* site 35 bp upstream of the ATG (including the RBS) and extended past the internal *HindIII* site. This fragment was cloned as a *SmaI*-*HindIII* fragment into the *SmaI*-*HindIII* site of pSJ2882-MCS. The 3' end was amplified from the *HindIII* site to 192 bp downstream of the stop codon, adding a *NotI* site, and was cloned as a *HindIII*-*NotI* fragment downstream of the 5' end.

The *amyQ* promoter (the promoter of a gene encoding a *Bacillus licheniformis* amylase called BANTM, Novo Nordisk A/S, Bagsværd, Denmark) was PCR-amplified using primers 37 and 38 listed below according to the amplification conditions described in Example 9:

Primer 37:

5'-TTTGGCCTTAAGGGCCTGCAATCGATTGTTTGAGAAAAGAAG-3' (*SfiI* and *ClaI* sites underlined, respectively) (SEQ ID NO:37)

Primer 38:

5'-TTTGAGCTCCATTTTCTTATACAAATTATATTTTACATATCAG-3' (*SstI* site underlined) (SEQ ID NO:38)

The *amyL* promoter (the promoter of a gene encoding a *Bacillus amyloliquefaciens* amylase called TERMAMYLTM, Novo Nordisk A/S, Bagsværd, Denmark) was PCR amplified.

as described in Example 9 from pPL1759 (Figure 4), a pUB110-based plasmid containing the *amyL* promoter. Primer term1Sfi was used in the amplification to add an *SfiI* site to the 5' end and primer 2iSfi was used to add a *SacI* site to the 3' end:

Primer term1Sfi: 5'-CCAGGCCTTAAGGGCCGCATGCGTCCTTCTTTG-3' (SEQ ID NO:39)

Primer 2iSfi: 5'-CCAGAGCTCCTTTCAATGTAACATATGA-3' (SEQ ID NO:40)

The *amyQ* promoter (BANTM promoter) and *amyL* promoter (TERMAMYLTM promoter) were then inserted upstream of the reconstructed gene into the *SfiI*-*SmaI* sites as *SfiI*-*Ecl136II* (blunt) fragments to produce p170BAN and p170TERM, respectively.

Example 13: Sequence analysis of the *Bacillus* JP170 protease gene

The reconstructed *Bacillus* JP170 protease gene was sequenced using an Applied Biosystems Model 377 Sequencer according to the manufacturer's instructions.

DNA sequence analysis of the reconstructed protease gene revealed an open reading frame of 1923 bp as shown in Figure 5 (SEQ ID NO:41). The deduced amino acid sequence (SEQ ID NO:42) as shown in Figure 5 consists of 641 amino acids including a 33 amino acid signal sequence and a 175 amino acid prepro region. The entire protein, including the signal sequence and prepro region, has 77% identity to the protease disclosed in JP 4197182, and the deduced mature protein has 89% identity to the same protease (Figure 6, SEQ ID NO:43) as determined by GeneAssist software (PE Applied Biosystems, Inc., Foster City, CA) and LaserGene software (DNASTAR, Inc., Madison, WI). Notably, it also contains the C-terminal extension seen in the protease disclosed in JP 4197182. The best homology in the protein database was to subtilisin precursor where the homology was only 35% identity (Figure 6, SEQ ID NO:44) as determined by GeneAssist.

Example 14: Transformation of *Bacillus subtilis* with p170BAN and p170TERM

Plasmids p170BAN and p170TERM were transformed into competent cells of *Bacillus subtilis* strain A164Δ5 according to the method of Petit *et al.*, 1990, *supra*, and selected for chloramphenicol resistance.

Transformants were patched onto TBAB plates containing 5 μg of chloramphenicol per ml and 1% milk and incubated at 37°C overnight to test for protease production. Strains containing either p170BAN or p170Term made faint halos when compared to strains containing the vector only, which made no halos.

Plasmid p170BAN was also transformed into competent cells of *Bacillus subtilis* strain 168 *aprE*- *nprE*- *amyE*- *spoIIIE*::*Tn917* as described above. One transformant designated

Bacillus subtilis LC20 produced zones on 1% milk-TBAB plates.

Example 15: Integration of pLC20 and pLC21 into *Bacillus subtilis*

To construct the integration vector pCAsub2, the neomycin resistance gene of pPL2419 (Figure 7) was excised by digestion with *Bcl*II and *Bgl*II and replaced with the chloramphenicol acetyltransferase (*cat*) gene-containing *Bam*HI fragment from pMI1101 (Youngman *et al.*, 1984, *Plasmid* 12: 1-9) to create plasmid pPL2419-*cat*. (*Bam*HI sticky ends are compatible with *Bcl*II and *Bgl*II sticky ends.) Then, the multiple cloning site (MCS) of pPL2419-*cat* was replaced with a new MCS containing *Sfi*I and *Not*I sites created by annealing the two oligonucleotides together shown (SEQ ID NO:45 and SEQ ID NO:46):

5'-AGCTTGGCCTTAAGGGCCCGATATCGGATCCGCGGCCGCTGCAGGTAC-3'

(*Hind*III and *Kpn*I compatible sites are underlined, *Sfi*I and *Not*I sites are double-underlined) (SEQ ID NO:45)

5'-CTGCAGCGGCCGCGGATCCGATATCGGGCCCTTAAGGCCA-3' (SEQ ID NO:46)

The annealed oligonucleotides were ligated to *Hind*III and *Kpn*I-cut pPL2419-*cat* to generate p2419MCS5-*cat*. Then, nucleotides 942 to 1751 of *amyE* (GenBank Locus BSAMYL, accession numbers V00101, J01547) were PCR-amplified using primers containing *Not*I and *Kpn*I (*Asp*718) linkers (SEQ ID NO:47 and SEQ ID NO:48) and *Bacillus subtilis* strain A164 Δ5 chromosomal DNA as template, and inserted into *Not*I and *Asp*718-digested p2419MCS5, generating integration vector pCAsub2 (Figure 8), CAsub referring to chloramphenicol resistance, *amylase* homology, for use in a *subtilis* host.

5'-GCGGCCGCGATTTCCAATGAG-3' (nucleotides added to create *Not*I site are underlined) (SEQ ID NO:47)

5'-GGTACCTGCATTTGCCAGCAC-3' (nucleotides added to create *Asp* 718I site are underlined) (SEQ ID NO:48)

Integration of this vector alone into *Bacillus subtilis* 168 and plating on starch azure overlay plates showed complete elimination of *amylase* activity.

The *amyQ* promoter and *amyL* promoter *Bacillus* JP170 protease gene cassettes were isolated from the pSJ2882-MCS-based plasmids p170BAN and p170TERM and cloned into the *Sfi*I-*Not*I sites of the *Bacillus* integration vector pCAsub2 to produce pLC20 and pLC21, respectively. pSJ2882-MCS is unable to replicate independently in *Bacillus* and therefore must integrate into the chromosome to be stably maintained. It contains a truncated version of the *amyE* gene which serves as a source of homology, and integration by a single crossover results

in insertion of the entire plasmid at the *amyE* locus.

pLC20 (*amyQ* promoter) and pLC21 (*amyL* promoter) were transformed into competent cells of *Bacillus subtilis* strains A164Δ5 and A1630Δ5 according to the method of Petit *et al.*, 1990, *supra*. The integrants were designated *Bacillus subtilis* A164Δ5-B-JP170, *Bacillus subtilis* A164Δ5-T-JP170, *Bacillus subtilis* A1630Δ5-B-JP170, and *Bacillus subtilis* A1630Δ5-T-JP170 where B is the BANTM promoter, T is the TERMAMYLTM promoter, and JP170 is the protease gene. Chloramphenicol-resistant transformants of each were tested for protease production on 1% milk-TBAB plates.

All transformants tested made halos that were larger and more distinct than the multicopy pSJ2882MCS-based transformants. The presence of the *Bacillus* JP170 protease and integration at the *amyE* locus were verified by PCR as described in Example 16.

Example 16: Integration screening

Putative integrants described in Example 15 were screened by PCR to verify the presence of the protease gene and to verify integration into the *amyE* locus. Genomic DNA from the putative integrants was prepared by resuspending a single colony in 100 μl of H₂O, freezing in dry ice for 5 minutes, followed by boiling for 5 minutes, then repeating the cycle 3 times. Suspensions were centrifuged for 10 minutes. PCR reactions using 5 μl of supernatant were set up as described in Example 9 using the following protease primers:

17020: 5'-GCTGCACTATTGTCTTCTG-3' (SEQ ID NO:49)
17025: 5'-CAGCAACTGCTACAATCTG-3' (SEQ ID NO:50)

The following primers were used for screening integration:

17037: 5'-GTGCAGGCTTACAATGTACCAG-3' (SEQ ID NO:51)
LCamyREV: 5'-GCATTACCTGGCTCCAATGATTC-3' (SEQ ID NO:52)

If the protease was present in the strain, then amplification with the protease primers would result in a 665 bp band. If the protease gene was integrated at the *amyE* locus, then amplification would result in a 1555 bp band using the integration primers.

Agarose gel electrophoresis of the resulting PCR products yielded a 1555 bp band confirming the integration of the *Bacillus* JP170 protease gene into the chromosome.

Example 17: Amplification of the *Bacillus* JP170 protease gene expression cassettes

The *amyQ* promoter (BANTM promoter) and *amyL* promoter (TERMAMYLTM promoter) *Bacillus* JP170 protease gene cassettes were amplified in the integrated strains *Bacillus subtilis* A164Δ5-B-JP170, *Bacillus subtilis* A164Δ5-T-JP170, *Bacillus subtilis*

A1630Δ5-B-JP170, and *Bacillus subtilis* A1630Δ5-T-JP170 strains. This was achieved by plating on TBAB plates containing successively higher chloramphenicol concentrations of 15, 30, 45, 60, and 80 μg per ml.

5 The stability of the protease integration after amplification was confirmed by patching on TBAB plates containing 1% milk at each chloramphenicol concentration. Production of halos showed 100% stability. After a few hours, amplified strains produced halos comparable in size to halos produced overnight by unamplified strains.

Example 18: Copy number determination

10 Southern blots were performed to estimate the copy number of the *Bacillus* JP170 protease gene expression cassettes in the amplified versus the unamplified versions of *Bacillus subtilis* A164Δ5-T-JP170 and *Bacillus subtilis* A1630Δ5-B-JP170 strains. Genomic DNA prepared from the strains according to the Bacterial DNA Isolation Protocol described in the Qiagen Genomic DNA Handbook (Qiagen, Chatsworth, CA) according to the manufacturer's
15 instructions was cut with *Hind*III, ran on a 0.8% agarose gel, blotted using PosiBlot Pressure Blotter and Pressure Control Station (Stratagene, La Jolla, CA), and hybridized and detected using probe 1/291 (Example 9) and the DIG System Hybridization and Detection Kit (Boehringer Mannheim, Indianapolis, IN) according to the manufacturers' instructions. Using the Storm Imaging System Model 860 (Molecular Dynamics, Sunnyvale, CA) according to the
20 manufacturer's instructions, it was estimated that the cassettes were amplified at least four times in each strain.

The Southern blot of the amplified *Bacillus subtilis* A164Δ5-T-JP170 showed a 300 bp deletion in the *amyL* promoter (TERMAMYL™ promoter) *Bacillus* JP170 protease gene cassette. However, SDS-PAGE analysis using Novex 14% Tris-Glycine Precast Gel-1.0 mm X
25 15 well and Novex DryEase Mini Gel Drying System (Novel Experimental Technology, San Diego, CA) according to the manufacturer's instructions showed that the expression of the *Bacillus subtilis* JP170 protease gene was not affected by this deletion.

Using a series of PCR reactions, it was established that the deletion is 5' of the *Bacillus* JP170 protease gene and encompasses the *amyL* promoter. The PCR reactions were performed
30 using several primers described *supra* and the following primers:

17021: 5'-CCAATAGTAGAAGGACTG-3' (SEQ ID NO:53)

RB1701: 5'-CTTCAGATTGGAAAGCGAGCGGACGGAATCATTGATC-3' (SEQ ID NO:54)

RB1702: 5'-CTCAGCTTGAAGAAGTGA-3' (SEQ ID NO:55)

35 RB1703: 5'-GAAGCAGAGAGGCTATTG-3' (SEQ ID NO:56)

RB1704: 5'-GAAAATATAGGGAAAATGT-3' (SEQ ID NO:57)

The PCR reactions were performed using the following primer pairs: 17037/17036Not, Term1Sfi/RB1701, RB1702/17021, RB1703/17021, RB1704/17021, 17036Not/Term1Sfi, 17020/17025, 170Sma/17021, M13-48Rev./17021 with 5 µg of 40 µg/ml template DNA, 2.5 µl
5 10X PCR buffer (Perkin-Elmer, Foster City, CA) containing 15 mM MgCl₂, 1 µl of 10 mM MgCl₂, 5 µl of 1 mM dNTP mix, 2.5 µl of 5 pmol/µl of each primer pair, 0.125 µl of 5 U/µl AmpliTaq Gold polymerase (Perkin-Elmer, Foster City, CA), and 6.375 µl of deionized water were used in each PCR reaction. Reactions were incubated in a Stratagene Robocycler 40 programmed for 1 cycle at 96°C for 10 minutes, 30 cycles each at 96°C for 1 minute, 55°C for
10 1 minute, and 72°C for 1 minute, and 1 cycle at 72°C for 5 minutes.

Since the *amyL* promoter is not present in the amplified *Bacillus subtilis* A164Δ5-T-JP170, the pUC19 sequence (*lacZ* promoter) found upstream of the *amyL* promoter probably served as the driving promoter for the *Bacillus* JP170 gene.

Reamplification of *Bacillus subtilis* A164Δ5-T-JP170 by plating on increasing
15 concentrations of chloramphenicol as described in Example 17 was performed in order to obtain a deletion-free promoter/protease cassette. Genomic DNA from *Bacillus subtilis* A164Δ5-T-JP170 was prepared by resuspending a single colony in 100 µl of deionized water, boiling for 5 minutes, followed by freezing for 5 minutes, then repeating this cycle three times. The suspensions were centrifuged for 10 minutes. The PCR reactions were set up as mentioned
20 above using 5 µl of supernatant as template DNA and the primer pair Term1Sfi/17021. At a chloramphenicol concentration of 20 µg/ml, it was shown that a deletion was present in this newly amplified version.

Retransformation of *Bacillus subtilis* A164Δ5 with pLC21 was performed in order to obtain a deletion-free promoter/protease cassette. PCR using the primer pair M13-48
25 Reverse/17021 as described above, it was shown that this unamplified strain was deletion free. This strain was amplified by successive plating on increasing concentrations of chloramphenicol as described in Example 17. PCR reactions using the primer pair M13-48Reverse/17021 showed that the amplified version (up to 40 µg/ml chloramphenicol) was deletion free. However, the deletion-free amplified version was difficult to grow and produced
30 very small halos on 1% milk-TBAB plates when compared to the amplified strain containing the *amyL* deletion.

The Southern blot of *Bacillus subtilis* A1630Δ5-B-JP170, using the same protocol as for *Bacillus subtilis* A164Δ5-T-JP170, did not show any deletion in the promoter/protease cassette.

Example 19: Expression of *Bacillus* JP170 protease in shake flasks

Bacillus subtilis A164Δ5-B-JP170, *Bacillus subtilis* A164Δ5-T-JP170, *Bacillus subtilis* A1630Δ5-B-JP170, and *Bacillus subtilis* A1630Δ5-T-JP170 strains were cultivated in shake flasks at 37°C and 250 rpm for 5 days containing 50 ml of PS-1 medium composed of 10% sucrose, 4% soybean flour, 0.42% anhydrous disodium phosphate, and 0.5% calcium carbonate supplemented with 5 μg of chloramphenicol per ml. In addition, *Bacillus subtilis* A164Δ5::pCAsub2 containing the integration vector was used as a negative control.

The stability of the protease integration was confirmed via casein plating at the beginning and at the end of each assay as described in Example 18. In each instance, the integration was 100% stable as shown by the production of large halos overnight (halos can be observed within a few hours).

SDS-PAGE analysis using Novex Precast Gels as described in Example 18 was performed to determine the expression levels in both assays. When the four strains were compared, it was observed that *Bacillus subtilis* A164Δ5-T-JP170 expression was greater compared to *Bacillus subtilis* A164Δ5-B-JP170. The opposite was true for *Bacillus subtilis* A1630Δ5 strain where expression of *Bacillus subtilis* A1630Δ5-B-JP170 was greater compared to *Bacillus subtilis* A1630Δ5-T-JP170. The negative control produced no detectable JP170 protease.

Example 20: Comparison of *Bacillus* sp. JP170 protease to SAVINASE™

Wash tests were performed to compare the efficacy of the *Bacillus* sp. JP170 protease (SP444) to SAVINASE™. The *Bacillus* sp. JP170 protease was obtained as described in WO 88/01293. SAVINASE™ was obtained from Novo Nordisk A/S, Bagsværd, Denmark.

The experimental conditions of the wash tests are enumerated below in Table 2.

25

Table 2

	Protease Model Detergent	Koso Top Detergent
Detergent Dose	3 g/l	0.7 g/l
pH	9.5	10.5
Wash Time	15 minutes	10 minutes
Temperature	15°C	20°C
Water Hardness	5.6°dH	2.8°dH

30

	~1 mM Ca ²⁺ /Mg ²⁺	~0.5 mM Ca ²⁺ /Mg ²⁺
Enzyme Concentration	0, 3, 6, 9, 12, 15, 30, 60, 90 nM	
Test Method	Miniwash	
Swatch/Volume	5 swatches (2.5 cm)/50 ml	
5 Test Material	Grass on cotton (rinsed in water)	

Koso Top (Lion Corp., Tokyo, Japan) is a commercial detergent, and therefore, the protease in the detergent was inactivated before the wash tests were performed. The protease
 10 was inactivated by heating a solution of 10 g of detergent in 100 ml deionized water to 85°C in a microwave oven.

The model detergent was composed of 25% STP (Na₅P₃O₁₀), 25% Na₂SO₄, 10% Na₂CO₃, 20% LAS (Nansa 80S), 5% NI (Dobanol 25-7), 0.5% Na₂Si₂O₅, 0.5% carboxymethylcellulose (CMC), and 9.5% water. The pH was adjusted to 9.5.

15 Measurement of remission (R) on the test material was performed at 460 nm using an Elrepho 2000 photometer (without UV). The measurements were fitted to the expression:

$$\Delta R = \{[(a)(\Delta R_{\max})(c)]/[\Delta R_{\max} + (a)(c)]\} + b$$

The improvement factor (IF) was calculated using the initial slope: $IF = a/a_{\text{ref}}$. ΔR is the wash effect of the enzyme in remission units; a is the initial slope of the fitted curve ($c \rightarrow 0$); a_{ref} is the
 20 initial slope for the reference enzyme; b is the intersection of the fitted curve and the y-axis; c is the enzyme concentration in nanomoles active enzyme per liter, and ΔR_{\max} is the theoretical maximum wash effect of the enzyme in remission units ($c \rightarrow \infty$).

The results of the wash tests demonstrated that the JP170 protease possessed an IF of 6.2 compared to 1.0 for SAVINASE™ in the model detergent as shown in Table 3. The JP170
 25 protease also had an IF of 4.6 compared to 1.0 for SAVINASE™ in the Koso Top detergent.

Table 3

Protease	Concentration	Improvement factor	
		Model Detergent	Koso Top
30 SAVINASE™	8.1×10^{-4} M	1.0	1.0
JP170 (SP444)	3.77×10^{-5} M	6.2	4.6

35 The wash results in the model detergent shown in Figure 9 demonstrated that the JP170

protease (SP444) performed significantly better than SAVINASE™ in removing grass stain from cotton.

The wash results in the Koso Top detergent shown in Figure 10 demonstrated that the JP170 protease (SP444) performed significantly better than SAVINASE™ in removing grass stain from cotton.

Deposit of Biological Materials

The following biological material has been deposited under the terms of the Budapest Treaty with the Agricultural Research Service Patent Culture Collection, Northern Regional Research Center, 1815 University Street, Peoria, Illinois, 61604, and given the following accession number:

Deposit	Accession Number	Date of Deposit
<i>Bacillus subtilis</i> LC20 (p170BAN)	NRRL B-21680	April 4, 1997

15

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: Sloma, Alan
Lynne, Christianson

(ii) TITLE OF THE INVENTION: Nucleic Acids Encoding A Polypeptide
Having Protease Activity

(iii) NUMBER OF SEQUENCES: 57

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Novo Nordisk of North America
(B) STREET: 405 Lexington Avenue
(C) CITY: New York
(D) STATE: NY
(E) COUNTRY: USA
(F) ZIP: 10174

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ for Windows Version 2.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: to be assigned
(B) FILING DATE: 12-JUN-1998
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Starnes, Robert L.
(B) REGISTRATION NUMBER: 41,324
(C) REFERENCE/DOCKET NUMBER: 5251.200-US

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 212-867-0123
(B) TELEFAX: 212-878-9655
(C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAGCTCACAG AGATACGTGG GC

22

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GGATCCACAC CAAGTCTGTT CAT

23

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GGATCCGCTG GACTCCGGCT G

21

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AAGCTTATCT CATCCATGGA AA

22

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AAGCTTAGGC ATTACAGATC

20

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CGGATCTCCG TCATTTTCCA GCCCGATGCA GCC

33

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GGCTGCATCG GGCTGGAAAA TGACGGAGAT CCG

33

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GATCACATCT TTCGGTGG

18

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CGTTTATGAG TTTATCAATC

20

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

AGACTTCCCA GTTTGCAGGT

20

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CAAACGGGA AGTCTCGACG GTTCATTCTT CTCTC

35

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

TCCAACAGCA TTCCAGGCTG

20

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GCGAATTCTA CCTAAATAGA GATAAAATC

29

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GTTTACCGCA CCTACGTCGA CCCTGTGTAG CCTTGA

36

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TCAAGGCTAC ACAGGGTCGA CGTAGGTGCG GTAAAC

36

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GCAAGCTTGA CAGAGAACAG AGAAGCCAG

29

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CGTCGACGCC TTTGCGGTAG TGGTGCTT

28

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CGCGGCCGCA GGCCCTTAAG GCCAGAACCA AATGAA

36

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 34 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TGGCCTTAAG GGCCTGCGGC CGCGATTTC AATG

34

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GAAGCTTCTT CATCATCATT GGCATACG

28

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AAGCTTTGAA TGGGTGTGG

19

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CCGCTTGTC TTTCATCCCC TGAAACAAC GTACCG

36

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 34 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CAGTTGTTTC AGGGGATGAA AGAACAAGCG GCTG

34

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

CTGACATGAG GCACTGAC

18

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Asn	Asp	Val	Ala	Arg	Gly	Ile	Val	Lys	Ala	Asp	Val	Ala	Gln	Asn	Asn
1				5				10					15		
Phe	Gly	Leu	Tyr	Gly	Gln	Gly	Gln	Ile	Val	Ala	Asp	Thr	Gly	Leu	Asp
		20					25						30		
Thr	Gly	Arg	Asn	Asp	Ser										
			35												

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Gly	Ala	Ala	Asp	Val	Gly	Leu	Gly	Phe	Pro	Asn	Gly	Asn	Gln	Gly	Trp
1				5				10					15		
Gly	Arg	Val	Thr	Leu	Asp	Lys									
				20											

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CCCCANCCNT GNTTNCNTT NGGNAANCC

29

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

GGNATNGTNA ANGCGANGT NGCNCANAAN AANTTNGG

38

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

TANGGNCANG GNCANATNGT NGCNGTNGCN GANACNGG

38

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

GTAGGTTTT C GGTGCCCCA ACTGTAATCG C

31

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GGTCCTACTA GAGATGGACG TATTAAGCCG G

31

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

CTCCCCCGGG GATGTGTTAT AAATTGAGAG GAG

33

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

CCTCGTGAAG AGAATTGAGC AACATGG

27

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

GCGATTACAG TTGGGGCAAC C

21

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

GCGGCCGCGT ACTCTCATCA ATTTCCAAG C

31

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

GCGGCCGCGT CATAAACGTT GCAATCGTGC TC

32

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

TTTGGCCTTA AGGGCCTGCA ATCGATTGTT TGAGAAAAGA AG

42

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 43 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

TTTGAGCTCC ATTTTCTTAT ACAAATTATA TTTTACATAT CAG

43

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

CCAGGCCTTA AGGGCCGCAT GCGTCCTTCT TTG

33

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

CCAGAGCTCC TTTCAATGTA ACATATGA

28

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3003 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

CTTAGGCAAG	CTTTACTCTA	TACAGAGATT	ACATCCTCAA	GCCATTGAAG	AATTCGAAAA	60
AAGTTATTAT	TTAAAAGAGG	ATAGGGGGTT	AGACAGTAAA	TTAAATTCGA	TTTATTGTCT	120
TTTGATGGAA	TACGATAACA	TGGAAGATTC	TACTCAATGT	AGAAAATGGT	TAGAAATTGG	180
GAAATCTTTG	CTAACTAGTC	CAGACGAATT	GGTAGAATAT	CATTATTATT	TCACCATTTT	240
TGACTATGTC	CTAGCAGACA	ATATGGATGA	GCTTGATGTC	TATTTCCAAG	AAGTCGTTTT	300
ACCTTTTTTC	AACAACAAGA	TTTAAAAGAA	CCAATTATTA	AATATGCAGA	GAGGCTCGCC	360
ATCTATTTTG	AATCTTGTTA	TAAATACAAA	AAAGCAAGCT	ACTACTATTC	GTTATGCTAC	420
CAAGAAATTA	AAGAACAAC	TTTTTTTATAC	TAAGGGGAGG	GTAATATGAA	AAAAAACTG	480
TTGCTTGTAG	TTTGTAGTTG	AATTCCTTTT	TTAGTAGGTA	CTTTGGAAAA	ATCTATTCAA	540
GAGCCTCAAG	TAATTGCACA	TGGCGAGGTT	ACTGCTTTAA	AAGATGAACA	TCCTGAGCCG	600
CTTCCAAATG	GTTAAAAACA	ATAAAGAACT	TTCTCTACTG	GAGAGGGTTC	TTTTTTTCTT	660
TCATTTTTTT	AGAAAATATT	GAATGGTCGC	TGTAGTCTGG	CTTGACAGTA	ATTTTCCATT	720
GGGAAAGTAT	GAGCCCAAAA	AGCGAATTAT	GAAGCTATTT	TAATCTGAAT	TTTCCCAATA	780
TAAAGTTTTT	GTTTCCTGTG	ATAAATTAAT	GATGTGTTAT	AAATTGAGAG	GAGTTGAGCT	840
ATAGAATGAG	AAAGAAAGGA	TCGAAGAGGG	TTTTTTTATC	CGTTTTATCA	GTTGCTGCAC	900
TATTGTCTTC	TGTTGCTTTA	AGCAGTCCTT	CTACTATTGG	GGCGAACAAT	TTTGAATTGG	960
ACTTTAAGGG	GATAGAGACA	CTTACGCTAG	AGAAGGCTGC	CACCAAGCAA	GGAAAAACGG	1020
GAAAGGCATC	TTTTCTTGTA	AACTCTGAAA	ATGTGAAAAT	CCCAAAGAGT	ATTCAAAAGA	1080
AACTAGAAGT	AGTTCCAGCG	GATAACAAGC	TATATATCGT	TCAATTTGAC	GGACCTATTT	1140
TAGAGGAAAC	GCAACTTCAA	CTAGAGAAGA	CGGGAGCGAA	AATTCCTCGAT	TACATACCAG	1200
ATTACGCTTA	TATTGTGCGA	TATGATGGGG	ATGTAAAGGC	CGTAACTAAC	GCAATTGCGC	1260

ATTTGGAATC	GGTTGAACCA	TATTTACCTT	TATATAAAAT	AGACCCGCAA	TTATTTTCCA	1320
GAGGAGCTTC	TGAATTAGTA	GAAACAGTAG	CTTTAGATAA	AAAGCAAAGA	AGTAAAGAAG	1380
TACGTTTAAG	AGGATTGGAA	CAAATTGCCC	AATACGCGAC	AAATAATGAT	GTATTATACG	1440
TAACCCCAAA	GCCTGAATAC	GAAGTTTGA	ATGACGTGGC	CCGTGGCATT	GTGAAAGCAG	1500
ACGTCGCACA	AAATAACTTT	GGCTTATATG	GACAAGGACA	GATTGTAGCA	GTTGCTGATA	1560
CTGGGCTTGA	TACAGGAAGA	AATGACAGTT	CGATGCATGA	AGCATTCCGC	GGTAAGATTA	1620
CCGCACTATA	TGCACTGGGC	AGAACGAATA	ACGCCAATGA	TCCAAATGGA	CATGGAACCC	1680
ATGTTGCTGG	ATCTGTGTTA	GGAAATGCTA	CAAATAAAGG	GATGGCACCG	CAAGCCAATC	1740
TAGTCTTTCA	ATCTATTATG	GATAGTGGTG	GAGGGCTGGG	AGGACTACCT	GCTAATCTAC	1800
AAACATTATT	CAGTCAAGCA	TATAGTGCTG	GAGCGAGAAT	TCATACGAAT	TCATGGGGGG	1860
CTCCAGTAAA	CGGTGCCTAT	ACGACAGACT	CTCGAAATGT	TGATGATTAT	GTGAGAAAAA	1920
ATGATATGAC	GATTCTTTTT	GCGGCCGGAA	ATGAGGGACC	AGGTAGCGGT	ACAATCAGTG	1980
CACCAGGAAC	AGCAAAAAAT	GCGATTACAG	TTGGGGCAAC	CGAAAACCTA	CGTCCAAGCT	2040
TCGGATCTTA	TGCGGATAAT	ATTAACCATG	TTGCTCAATT	CTCTTCACGA	GGTCCTACTA	2100
GAGATGGACG	TATTAAGCCG	GACGTCATGG	CACCAGGTAC	GTATATTCTC	TCTGCTAGAT	2160
CATCATTAGC	TCCAGATTCC	TCATTCTGGG	CAAACCATGA	TAGTAAATAT	GCCTACATGG	2220
GTGGTACTTC	TATGGCTACT	CCAATTGTAG	CAGGTAATGT	TGCACAATTA	AGGGAGCATT	2280
TTGTGAAAAA	TAGAGGGGTA	ACTCCTAAGC	CTTCCCTTTT	AAAAGCTGCT	TTAATTGCAG	2340
GTGCTGCGGA	TGTTGGACTT	GGCTTTCCAA	ATGGTAACCA	AGGATGGGGA	AGAGTAACGT	2400
TAGATAAATC	CCTAAATGTC	GCATTGTGTA	ATGAAACGAG	CCCTTTATCA	ACAAGTCAAA	2460
AAGCAACATA	TTCGTTTACG	GCTCAAGCTG	GTAAACCCTT	AAAAATATCA	CTTGTTTGGT	2520
CAGATGCACC	AGGTAGCACG	ACGGCATCAC	TAACTTTAGT	GAATGATTTA	GACTTAGTAA	2580
TCACTGCACC	AAATGGAAC	AAATACGTCG	GAAATGACTT	TACAGCACCG	TATGATAACA	2640
ATTGGGATGG	CAGAAACAAC	GTGGAATAATG	TGTTTATCAA	TGCTCCTCAA	AGCGGAACGT	2700
ATACAGTCGA	AGTGCAGGCT	TACAATGTAC	CAGTAAGTCC	GCAAACCTTT	TCTTTAGCGA	2760
TTGTACATTA	AAATATTGGA	AGGAAGAGTT	GTTGATGAAT	ATATCAGCAG	CTCTTTTTTT	2820
GATTAAGCTC	TTTTCGTAAA	GGTTGTTGCT	TTAAGTCGGT	AAAAAGTCGG	TATTTGGA	2880
TTTTACCAGT	CATTTTGCTT	GGGAAATTGA	TGAGAGTACT	TTCATTACTG	ATGGAAAAGA	2940
GCACGATTGC	AACGTTTATG	ACGGGGTGAT	TTCTATTTAC	GAAAAGCAAC	AAAGTATGCG	3000
AAA						3003

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 641 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Met	Arg	Lys	Lys	Gly	Ser	Lys	Arg	Val	Phe	Leu	Ser	Val	Leu	Ser	Val
1				5					10				15		
Ala	Ala	Leu	Leu	Ser	Ser	Val	Ala	Leu	Ser	Ser	Pro	Ser	Thr	Ile	Gly
			20					25					30		
Ala	Asn	Asn	Phe	Glu	Leu	Asp	Phe	Lys	Gly	Ile	Glu	Thr	Leu	Thr	Leu
		35					40					45			
Glu	Lys	Ala	Ala	Thr	Lys	Gln	Gly	Lys	Thr	Gly	Lys	Ala	Ser	Phe	Leu
		50				55					60				
Val	Asn	Ser	Glu	Asn	Val	Lys	Ile	Pro	Lys	Ser	Ile	Gln	Lys	Lys	Leu
65					70				75					80	
Glu	Val	Val	Pro	Ala	Asp	Asn	Lys	Leu	Tyr	Ile	Val	Gln	Phe	Asp	Gly
			85					90					95		
Pro	Ile	Leu	Glu	Glu	Thr	Gln	Leu	Gln	Leu	Glu	Lys	Thr	Gly	Ala	Lys
			100				105						110		
Ile	Leu	Asp	Tyr	Ile	Pro	Asp	Tyr	Ala	Tyr	Ile	Val	Glu	Tyr	Asp	Gly
		115				120					125				
Asp	Val	Lys	Ala	Val	Thr	Asn	Ala	Ile	Ala	His	Leu	Glu	Ser	Val	Glu
		130				135					140				
Pro	Tyr	Leu	Pro	Leu	Tyr	Lys	Ile	Asp	Pro	Gln	Leu	Phe	Ser	Arg	Gly
145				150					155					160	
Ala	Ser	Glu	Leu	Val	Glu	Thr	Val	Ala	Leu	Asp	Lys	Lys	Gln	Arg	Ser
			165					170						175	

Lys	Glu	Val	Arg	Leu	Arg	Gly	Leu	Glu	Gln	Ile	Ala	Gln	Tyr	Ala	Thr	180	185	190
Asn	Asn	Asp	Val	Leu	Tyr	Val	Thr	Pro	Lys	Pro	Glu	Tyr	Glu	Val	Leu	195	200	205
Asn	Asp	Val	Ala	Arg	Gly	Ile	Val	Lys	Ala	Asp	Val	Ala	Gln	Asn	Asn	210	215	220
Phe	Gly	Leu	Tyr	Gly	Gln	Gly	Gln	Ile	Val	Ala	Val	Ala	Asp	Thr	Gly	225	230	235
Leu	Asp	Thr	Gly	Arg	Asn	Asp	Ser	Ser	Met	His	Glu	Ala	Phe	Arg	Gly	245	250	255
Lys	Ile	Thr	Ala	Leu	Tyr	Ala	Leu	Gly	Arg	Thr	Asn	Asn	Ala	Asn	Asp	260	265	270
Pro	Asn	Gly	His	Gly	Thr	His	Val	Ala	Gly	Ser	Val	Leu	Gly	Asn	Ala	275	280	285
Thr	Asn	Lys	Gly	Met	Ala	Pro	Gln	Ala	Asn	Leu	Val	Phe	Gln	Ser	Ile	290	295	300
Met	Asp	Ser	Gly	Gly	Gly	Leu	Gly	Gly	Leu	Pro	Ala	Asn	Leu	Gln	Thr	305	310	315
Leu	Phe	Ser	Gln	Ala	Tyr	Ser	Ala	Gly	Ala	Arg	Ile	His	Thr	Asn	Ser	325	330	335
Trp	Gly	Ala	Pro	Val	Asn	Gly	Ala	Tyr	Thr	Thr	Asp	Ser	Arg	Asn	Val	340	345	350
Asp	Asp	Tyr	Val	Arg	Lys	Asn	Asp	Met	Thr	Ile	Leu	Phe	Ala	Ala	Gly	355	360	365
Asn	Glu	Gly	Pro	Gly	Ser	Gly	Thr	Ile	Ser	Ala	Pro	Gly	Thr	Ala	Lys	370	375	380
Asn	Ala	Ile	Thr	Val	Gly	Ala	Thr	Glu	Asn	Leu	Arg	Pro	Ser	Phe	Gly	385	390	395
Ser	Tyr	Ala	Asp	Asn	Ile	Asn	His	Val	Ala	Gln	Phe	Ser	Ser	Arg	Gly	405	410	415
Pro	Thr	Arg	Asp	Gly	Arg	Ile	Lys	Pro	Asp	Val	Met	Ala	Pro	Gly	Thr	420	425	430
Tyr	Ile	Leu	Ser	Ala	Arg	Ser	Ser	Leu	Ala	Pro	Asp	Ser	Ser	Phe	Trp	435	440	445
Ala	Asn	His	Asp	Ser	Lys	Tyr	Ala	Tyr	Met	Gly	Gly	Thr	Ser	Met	Ala	450	455	460
Thr	Pro	Ile	Val	Ala	Gly	Asn	Val	Ala	Gln	Leu	Arg	Glu	His	Phe	Val	465	470	475
Lys	Asn	Arg	Gly	Val	Thr	Pro	Lys	Pro	Ser	Leu	Leu	Lys	Ala	Ala	Leu	485	490	495
Ile	Ala	Gly	Ala	Ala	Asp	Val	Gly	Leu	Gly	Phe	Pro	Asn	Gly	Asn	Gln	500	505	510
Gly	Trp	Gly	Arg	Val	Thr	Leu	Asp	Lys	Ser	Leu	Asn	Val	Ala	Phe	Val	515	520	525
Asn	Glu	Thr	Ser	Pro	Leu	Ser	Thr	Ser	Gln	Lys	Ala	Thr	Tyr	Ser	Phe	530	535	540
Thr	Ala	Gln	Ala	Gly	Lys	Pro	Leu	Lys	Ile	Ser	Leu	Val	Trp	Ser	Asp	545	550	555
Ala	Pro	Gly	Ser	Thr	Thr	Ala	Ser	Leu	Thr	Leu	Val	Asn	Asp	Leu	Asp	565	570	575
Leu	Val	Ile	Thr	Ala	Pro	Asn	Gly	Thr	Lys	Tyr	Val	Gly	Asn	Asp	Phe	580	585	590
Thr	Ala	Pro	Tyr	Asp	Asn	Asn	Trp	Asp	Gly	Arg	Asn	Asn	Val	Glu	Asn	595	600	605
Val	Phe	Ile	Asn	Ala	Pro	Gln	Ser	Gly	Thr	Tyr	Thr	Val	Glu	Val	Gln	610	615	620
Ala	Tyr	Asn	Val	Pro	Val	Ser	Pro	Gln	Thr	Phe	Ser	Leu	Ala	Ile	Val	625	630	635
His																		640

(2) INFORMATION FOR SEQ ID NO:43:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 635 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Met	Lys	Gly	Lys	Lys	Arg	Val	Val	Leu	Ser	Val	Val	Ala	Ser	Ala	Ala
1				5					10					15	
Ile	Leu	Ala	Ser	Val	Met	Val	Ser	Ser	Pro	Thr	Ser	Gly	Ala	Asp	Phe
			20					25					30		
Gln	Val	Asn	Phe	Asn	Gly	Val	Lys	Ser	Leu	Glu	Asn	Ala	Ser	Leu	Val
		35				40						45			
Lys	Pro	Ile	Ser	Ser	Gly	Glu	Ala	Ser	Phe	Leu	Val	Asp	Thr	Glu	Asn
	50				55						60				
Ile	Asn	Ile	Pro	Lys	Gly	Ile	Gln	Lys	Lys	Leu	Glu	Ala	Val	Gln	Lys
65					70					75					80
Asp	Asn	Glu	Leu	Tyr	Ile	Val	Gln	Phe	Thr	Gly	Pro	Ile	Ser	Glu	Glu
				85				90						95	
Glu	Arg	Lys	Gly	Leu	Glu	Ser	Leu	Gly	Val	Ser	Ile	Leu	Asp	Tyr	Val
			100					105					110		
Pro	Asp	Tyr	Ala	Phe	Ile	Val	Gln	Tyr	Ser	Gly	Ala	Thr	Lys	Asn	Ile
		115				120						125			
Ser	Thr	Leu	His	Ser	Val	Glu	Asn	Val	Gln	Pro	Phe	Leu	Pro	Leu	Tyr
	130					135					140				
Lys	Ile	Asp	Pro	Glu	Leu	Leu	Thr	Lys	Gly	Ala	Ser	Gln	Leu	Val	Gln
145					150					155					160
Ala	Val	Ile	Leu	Asn	Thr	Lys	His	Glu	Asn	Lys	Asn	Met	Lys	Phe	Thr
				165				170						175	
Gly	Leu	Asp	Glu	Ile	Val	Gln	Tyr	Ala	Ala	Asn	Asn	Asp	Val	Leu	Tyr
			180					185					190		
Ile	Ser	Pro	Lys	Pro	Glu	Tyr	Glu	Leu	Met	Asn	Asp	Val	Ala	Arg	Gly
		195				200						205			
Ile	Val	Lys	Ala	Asp	Val	Ala	Gln	Asn	Asn	Tyr	Gly	Leu	Tyr	Gly	Gln
	210					215					220				
Gly	Gln	Leu	Val	Ala	Val	Ala	Asp	Thr	Gly	Leu	Asp	Thr	Gly	Arg	Asn
225					230					235					240
Asp	Ser	Ser	Met	His	Glu	Ala	Phe	Arg	Gly	Lys	Ile	Thr	Ala	Leu	Tyr
				245				250						255	
Ala	Leu	Gly	Arg	Thr	Asn	Asn	Ala	Ser	Asp	Pro	Asn	Gly	His	Gly	Thr
			260					265					270		
His	Val	Ala	Gly	Ser	Val	Leu	Gly	Asn	Ala	Leu	Asn	Lys	Gly	Met	Ala
		275				280						285			
Pro	Gln	Ala	Asn	Leu	Val	Phe	Gln	Ser	Ile	Met	Asp	Ser	Ser	Gly	Gly
	290					295					300				
Leu	Gly	Gly	Leu	Pro	Ser	Asn	Leu	Asn	Thr	Leu	Phe	Ser	Gln	Ala	Trp
305					310					315					320
Asn	Ala	Gly	Ala	Arg	Ile	His	Thr	Asn	Ser	Trp	Gly	Ala	Pro	Val	Asn
				325				330						335	
Gly	Ala	Tyr	Thr	Ala	Asn	Ser	Arg	Gln	Val	Asp	Glu	Tyr	Val	Arg	Asn
			340					345					350		
Asn	Asp	Met	Thr	Val	Leu	Phe	Ala	Ala	Gly	Asn	Glu	Gly	Pro	Asn	Ser
		355				360						365			
Gly	Thr	Ile	Ser	Ala	Pro	Gly	Thr	Ala	Lys	Asn	Ala	Ile	Thr	Val	Gly
	370					375					380				
Ala	Thr	Glu	Asn	Tyr	Arg	Pro	Ser	Phe	Gly	Ser	Ile	Ala	Asp	Asn	Pro
385					390					395					400
Asn	His	Ile	Ala	Gln	Phe	Ser	Ser	Arg	Gly	Ala	Thr	Arg	Asp	Gly	Arg
				405				410						415	
Ile	Lys	Pro	Asp	Val	Thr	Ala	Pro	Gly	Thr	Phe	Ile	Leu	Ser	Ala	Arg
			420					425					430		
Ser	Ser	Leu	Ala	Pro	Asp	Ser	Ser	Phe	Trp	Ala	Asn	Tyr	Asn	Ser	Lys
		435				440						445			
Tyr	Ala	Tyr	Met	Gly	Gly	Thr	Ser	Met	Ala	Thr	Pro	Ile	Val	Ala	Gly
	450					455					460				
Asn	Val	Ala	Gln	Leu	Arg	Glu	His	Phe	Ile	Lys	Asn	Arg	Gly	Ile	Thr
465					470					475					480
Pro	Lys	Pro	Ser	Leu	Ile	Lys	Ala	Ala	Leu	Ile	Ala	Gly	Ala	Thr	Asp
				485					490					495	
Val	Gly	Leu	Gly	Tyr	Pro	Ser	Gly	Asp	Gln	Gly	Trp	Gly	Arg	Val	Thr

			500					505				510				
Leu	Asp	Lys	Ser	Leu	Asn	Val	Ala	Tyr	Val	Asn	Glu	Ala	Thr	Ala	Leu	
		515					520					525				
Ala	Thr	Gly	Gln	Lys	Ala	Thr	Tyr	Ser	Phe	Gln	Ala	Gln	Ala	Gly	Lys	
		530					535					540				
Pro	Leu	Lys	Ile	Ser	Leu	Val	Trp	Thr	Asp	Ala	Pro	Gly	Ser	Thr	Thr	
545					550					555					560	
Ala	Ser	Tyr	Thr	Leu	Val	Asn	Asp	Leu	Asp	Leu	Val	Ile	Thr	Ala	Pro	
			565						570					575		
Asn	Gly	Gln	Lys	Tyr	Val	Gly	Asn	Asp	Phe	Ser	Tyr	Pro	Tyr	Asp	Asn	
		580						585					590			
Asn	Trp	Asp	Gly	Arg	Asn	Asn	Val	Glu	Asn	Val	Phe	Ile	Asn	Ala	Pro	
		595					600					605				
Gln	Ser	Gly	Thr	Tyr	Ile	Ile	Glu	Val	Gln	Ala	Tyr	Asn	Val	Pro	Ser	
	610					615					620					
Gly	Pro	Gln	Arg	Phe	Ser	Leu	Ala	Ile	Val	His						
625					630					635						

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 418 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

Met	Lys	Arg	Ser	Gly	Lys	Ile	Phe	Thr	Thr	Ala	Met	Leu	Ala	Val	Thr	
1				5				10						15		
Leu	Met	Met	Pro	Ala	Ile	Gly	Val	Ser	Ala	Asn	Arg	Gly	Asn	Ala	Ala	
		20						25					30			
Asp	Gly	Asn	Glu	Lys	Phe	Arg	Val	Leu	Val	Asp	Ser	Ala	Asn	Gln	Asn	
		35					40					45				
Asn	Leu	Lys	Asn	Val	Lys	Glu	Gln	Tyr	Gly	Val	His	Trp	Asp	Phe	Ala	
	50					55					60					
Gly	Glu	Gly	Phe	Thr	Thr	Asn	Met	Asn	Glu	Lys	Gln	Phe	Asn	Ala	Leu	
65				70					75						80	
Gln	Asn	Asn	Lys	Asn	Leu	Thr	Val	Glu	Lys	Val	Pro	Glu	Leu	Glu	Ile	
			85					90						95		
Ala	Thr	Ala	Thr	Asn	Lys	Pro	Glu	Ala	Leu	Tyr	Asn	Ala	Met	Ala	Ala	
		100						105					110			
Ser	Gln	Ser	Thr	Pro	Trp	Gly	Ile	Lys	Ala	Ile	Tyr	Asn	Asn	Ser	Asn	
		115					120					125				
Leu	Thr	Ser	Thr	Ser	Gly	Gly	Ala	Gly	Ile	Asn	Ile	Ala	Val	Leu	Asp	
	130					135					140					
Thr	Gly	Val	Asn	Thr	Asn	His	Pro	Asp	Leu	Ser	Asn	Asn	Val	Glu	Gln	
145				150					155						160	
Cys	Lys	Asp	Phe	Thr	Val	Gly	Thr	Asn	Phe	Thr	Asp	Asn	Ser	Cys	Thr	
			165					170						175		
Asp	Arg	Gln	Gly	His	Gly	Thr	His	Val	Ala	Gly	Ser	Ala	Leu	Ala	Asn	
		180						185					190			
Gly	Gly	Thr	Gly	Ser	Gly	Val	Tyr	Gly	Val	Ala	Pro	Glu	Ala	Asp	Leu	
		195					200					205				
Trp	Ala	Tyr	Lys	Val	Leu	Gly	Asp	Asp	Gly	Ser	Gly	Tyr	Ala	Asp	Asp	
	210					215					220					
Ile	Ala	Glu	Ala	Ile	Arg	His	Ala	Gly	Asp	Gln	Ala	Thr	Ala	Leu	Asn	
225				230						235					240	
Thr	Lys	Val	Val	Ile	Asn	Met	Ser	Leu	Gly	Ser	Ser	Gly	Glu	Ser	Ser	
			245					250						255		
Leu	Ile	Thr	Asn	Ala	Val	Asp	Tyr	Ala	Tyr	Asp	Lys	Gly	Val	Leu	Ile	
		260						265					270			
Ile	Ala	Ala	Ala	Gly	Asn	Ser	Gly	Pro	Lys	Pro	Gly	Ser	Ile	Gly	Tyr	
		275					280					285				
Pro	Gly	Ala	Leu	Val	Asn	Ala	Val	Ala	Val	Ala	Ala	Leu	Glu	Asn	Thr	
290						295						300				

Ile	Gln	Asn	Gly	Thr	Tyr	Arg	Val	Ala	Asp	Phe	Ser	Ser	Arg	Gly	His
305					310					315					320
Lys	Thr	Ala	Gly	Asp	Tyr	Val	Ile	Gln	Lys	Gly	Asp	Val	Glu	Ile	Ser
			325						330					335	
Ala	Pro	Gly	Ala	Ala	Val	Tyr	Ser	Thr	Trp	Phe	Asp	Gly	Gly	Tyr	Ala
			340					345					350		
Thr	Ile	Ser	Gly	Thr	Ser	Met	Ala	Ser	Pro	His	Ala	Ala	Gly	Leu	Ala
		355				360						365			
Ala	Lys	Ile	Trp	Ala	Gln	Ser	Pro	Ala	Ala	Ser	Asn	Val	Asp	Val	Arg
	370				375					380					
Gly	Glu	Leu	Gln	Thr	Arg	Ala	Ser	Val	Asn	Asp	Ile	Leu	Ser	Gly	Asn
385				390					395					400	
Ser	Ala	Gly	Ser	Gly	Asp	Asp	Ile	Ala	Ser	Gly	Phe	Gly	Phe	Ala	Lys
			405					410						415	
Val	Gln														

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

AGCTTGGCCT TAAGGGCCCG ATATCGGATC CGCGGCCGCT GCAGGTAC

48

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

CTGCAGCGGC CGCGGATCCG ATATCGGGCC CTTAAGGCCA

40

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

GCGGCCGCGA TTTCCAATGA G

21

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

GGTACCTGCA TTTGCCAGCA C

21

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

GCTGCACTAT TGTCTTCTG

19

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

CAGCAACTGC TACAATCTG

19

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

GTGCAGGCTT ACAATGTACC AG

22

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

GCATTTACCT GGCTCCAATG ATTC

24

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

CCAATAGTAG AAGGACTG

18

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

CTTCAGATTG GAAAGCGAGC GGACGGAATC ATTGATC

37

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

CTCAGCTTGA AGAAGTGA

18

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

GAAGCAGAGA GGCTATTG

18

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

GAAAATATAG GGAAAATGT

19

Claims

What is claimed is:

- 5 1. An isolated nucleic acid sequence encoding a polypeptide having protease activity, selected from the group consisting of:
 - (a) a nucleic acid sequence encoding a polypeptide having an amino acid sequence which has at least 95% identity with the amino acid sequence of SEQ ID NO:43;
 - (b) a nucleic acid sequence encoding a polypeptide having an amino acid sequence
10 which has at least 85% identity with the amino acid sequence of SEQ ID NO:42;
 - (c) a nucleic acid sequence having at least 95% homology with the mature polypeptide encoding region of the nucleic acid sequence of SEQ ID NO:41;
 - (d) an allelic variant of (a), (b), or (c); and
 - (e) a subsequence of (a), (b), (c), or (d), wherein the subsequence encodes a polypeptide
15 fragment which has protease activity.
2. The nucleic acid sequence of claim 1, which encodes a polypeptide having an amino acid sequence which has at least 95% identity with the amino acid sequence of SEQ ID NO:43.
- 20 3. The nucleic acid sequence of claim 1, which encodes a polypeptide having the amino acid sequence of SEQ ID NO:43, or a fragment thereof which has protease activity.
4. The nucleic acid sequence of claim 3, which encodes a polypeptide having the amino acid sequence of SEQ ID NO:43.
25
5. The nucleic acid sequence of claim 2, wherein the nucleic acid sequence encodes a polypeptide having protease activity obtained from a *Bacillus* strain.
6. The nucleic acid sequence of claim 1, which encodes a polypeptide having an amino
30 acid sequence which has at least 85% identity with the amino acid sequence of SEQ ID NO:42.
7. The nucleic acid sequence of claim 1, which encodes a polypeptide having the amino acid sequence of SEQ ID NO:42, or a fragment thereof which has protease activity.
- 35 8. The nucleic acid sequence of claim 7, which encodes a polypeptide having the amino acid sequence of SEQ ID NO:42.

9. The nucleic acid sequence of claim 6, wherein the nucleic acid sequence encodes a polypeptide having protease activity obtained from a *Bacillus* strain.
- 5 10. The nucleic acid sequence of claim 1, which has at least 95% homology with the mature polypeptide encoding region of the nucleic acid sequence of SEQ ID NO:41.
11. The nucleic acid sequence of claim 1, which has the nucleic acid sequence of SEQ ID NO:41.
- 10 12. The nucleic acid sequence of claim 10, wherein the nucleic acid sequence encodes a polypeptide having protease activity obtained from a *Bacillus* strain.
13. The nucleic acid sequence of claim 1, wherein the nucleic acid sequence encodes a
15 polypeptide having protease activity obtained from a *Bacillus* strain NCIB 12513.
14. The nucleic acid sequence of claim 1, which comprises the protease-encoding nucleic acid sequence contained in the plasmid p170BAN which is contained in *Bacillus subtilis* LC20 NRRL B-21680.
- 20 15. A nucleic acid construct comprising the nucleic acid sequence of claim 1 operably linked to one or more control sequences which direct the production of the polypeptide in a suitable expression host.
- 25 16. A recombinant expression vector comprising the nucleic acid construct of claim 15, a promoter, and transcriptional and translational stop signals.
17. The vector of claim 16, further comprising a selectable marker.
- 30 18. A recombinant host cell comprising one or more copies of the nucleic acid construct of claim 15.
19. The cell of claim 18, wherein the nucleic acid construct is contained on a vector.
- 35 20. The cell of claim 18, wherein the nucleic acid construct is integrated into the host cell genome.

21. The cell of claim 18, wherein the host cell is a bacterial cell.
22. The cell of claim 21, wherein the bacterial cell is a *Bacillus*, *Streptomyces*, or
5 *Pseudomonas* cell.
23. The cell of claim 22, wherein the *Bacillus* cell is a *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus firmus*,
10 *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*,
Bacillus stearothermophilus, *Bacillus subtilis*, or *Bacillus thuringiensis* strain
24. A method for producing a polypeptide having protease activity comprising (a) cultivating the host cell of claim 18 under conditions suitable for the production of the polypeptide; and (b) recovering the polypeptide.
15
25. A method for producing a mutant of a cell, which comprises disrupting or deleting the nucleic acid sequence of claim 1 or a control sequence thereof, which results in the mutant producing less of the polypeptide than the cell.
- 20 26. A mutant of a cell obtained by the method of claim 25.
27. The mutant cell of claim 26, which further comprises one or more copies of a nucleic acid sequence encoding a heterologous protein.
- 25 28. A method for producing a heterologous protein comprising
(a) cultivating the mutant cell of claim 27 under conditions suitable for production of the protein; and
(b) recovering the protein.




Fig. 1




Fig. 2




Fig. 3




Fig. 4

CTTAGGCAAGCTTTACTCTATACAGAGATTACATCCTCAAGCCATTGAAGAATTCGAAAAAAGTTATTATTTAAA 75
AGAGGATAGGGGGTTAGACAGTAAATTAATTCGATTTATTGTCTTTTGATGGAATACGATAACATGGAAGATTC 150
TACTCAATGTAGAAAATGGTTAGAAAATGGGAAATCTTTGCTAACTAGTCCAGACGAATTGGTAGAATATCATT 225
TTATTTTACCATTCTTTGACTATGCTCCTAGCAGACAATATGGATGAGCTTGATGTCTATTTCCAAGAAGTCGTTT 300
ACGTTTTTTTCAACAACAAGATTTAAAAGAACCAATTATTAATATGCAGAGAGGCTCGCCATCTATTTTGAATC 375
TTGTTATAAATACAAAAAGCAAGCTACTACTATTTCGTTATGCTACCAAGAAATTAAGAACAACCTTTTTTATA 450
CTAAGGGGAGGGTAATATGAAAAAAAACGTGTTGCTTGTAGTTTTAGTGGAAATCTTTTTTTAGTAGGTACTTT 525
GGAAAAATCTATTCAAGAGCCTCAAGTAATTGCACATGGCGAGGTTACTGCTTTAAAAGATGAACATCCTGAGCC 600
GCTTCCAAATGGTTAAAAACAATAAAGAACTTTCTCTACTGGAGAGGGTTCTTTTTTTCTTTTCATTTTTTAGAA 675
AATATTGAATGGTCGCTGTAGTCTGGCTTGACAGTAATTTTCCATTGGGAAAGTATGAGCCAAAAAGCGAATTA 750
TGAAGCTATTTTAATCTGAATTTTCCCAATATAAAGTTTTGTTTCTGTGATAAATTAATGATGTGTTATAAAT 825
TGAGAGGAGTTGAGCTATAGAATGAGAAAGAAAGGATCGAAGAGGGTTTTTTTATCCGTTTTATCAGTTGCTGCA 900
M R K K G S K R V F L S V L S V A A
CTATTGTCTTCTGTTGCTTTAAGCAGTCCTTCTACTATTGGGGCGAACAATTTGAATTGGACTTTAAGGGGATA 975
L L S S V A L S S P S T I G A N N F E L D F K G I
GAGACACTTACGCTAGAGAAGGCTGCCACCAAGCAAGGAAAAACGGGAAAGGCATCTTTTCTTGTAACCTCTGAA 1050
E T L T L E K A A T K Q G K T G K A S F L V N S E
AATGTGAAAATCCCAAAGAGTATTCAAAAGAACTAGAAGTAGTTCCAGCGSATAACAAGCTATATATCGTTCAA 1125
N V K I P K S I O K K L E V V P A D N K L Y I V O
TTTGACGGACCTATTTTAGAGGAAACGCAACTTCAACTAGAGAAGACGGGAGCGGAAAATTCTCGATTACATACCA 1200
F D G P I L E E T O L O L E K T G A K I L D Y I P
GATTACGCTTATATTGTCGAATATGATGGGGATGTAAAGGCCGTAACGCAATTGCGCATTTGGAATCGGTT 1275
D Y A Y I V E Y D G D V K A V T N A I A H L E S V
GAACCATATTTACCTTTATATAAAATAGACCCGCAATTATTTTCCAGAGGAGCTTCTGAATTAGTAGAAACAGTA 1350
E P Y L P L Y K I O P Q L F S R G A S E L V E T V
GCTTTAGATAAAAAGCAAAGAAGTAAAGAAGTACGTTTAAAGAGGATTGGAACAAATTGCCCAATACGCGACAAT 1425
A L D K K Q R S K E V R L R G L E O I A O Y A T N
AATGATGTATTATACGTAACCCCAAAGCCTGAATACGAAGTTTGAATGACGTGGCCCGTGGCATTGTGAAAGCA 1500
N D V L Y V T P K P E Y E V L N D V A R G I V K A
GACGTCGCACAAAATAACTTTGGCTTATATGGACAAGGACAGATTGTAGCASTTGCTGATACTGGGCTTGATACA 1575
D V A Q N N F G L Y G O G O I V A V A D T G L D T
GGAAGAAATGACAGTTGATGCATGAAGCATTCCGCGGTAAGATTACCGCACTATATGCACTGGGCAGAACGAAT 1650
G R N D S S H H E A F R G K I T A L Y A L G R T N
AACGCCAATGATCCAAATGGACATGGAACCCATGTTGCTGGATCTGTGTTAGGAAATGCTACAAATAAAGGGATG 1725
N A N D P N G H G T H V A G S V L G N A T N K G M
GCACCGCAAGCCAATCTAGTCTTTCAATCTATTATGGATAGTGSTGGAGGGCTGGGAGGACTACCTGCTAATCTA 1800
A P Q A N L V F Q S I M D S G G G L G G L P A N L
CAAACATTATTCAGTCAAGCATATAGTGCTGGAGCGAGAATTCATACGAATTCATGGGGGGCTCCAGTAAACGGT 1875
Q T L F S Q A Y S A G A R I H T N S W G A P V N G
GCCTATACGACAGACTCTCGAAATGTTGATGATTATGTGAGAAAAAATGATATGACGATTCTTTTTTGGGGCCGSA 1950
A Y T T D S R N V D O Y V R K N D M T I L F A A G
AATGAGGSACCAGGTAGCGGTACAATCAGTGCACCAGGAACAGCAAAAAATGCGATTACAGTTGGGGCAACCGAA 2025
N E G P G S G T I S A P G T A K N A I T V G A T E
AACCTACGTCCAAGCTTCGGATCTTATGCGGATAATATTAACCATGTTGCTCAATTCTTTCACGAGGTCCTACT 2100
N L R P S F G S Y A D N I N H V A O F S S R G P T
AGAGATGGACGTATTAAGCCGGACGTCATGGCACCAGGTACGTATATTCTCTGCTAGATCATCATTAGCTCCA 2175
R D G R I K P D V M A P G T Y I L S A R S S L A P
GATTCCTCATTCTGGGCAAACCATGATAGTAAATATGCCTACATGGGTGGTACTTCTATGGCTACTCCAATTGTA 2250
D S S F W A N H D S K Y A Y M G G T S M A T P I V

Fig. 5A

GCAGGTAATGTTGCACAATTAAGGGAGCATTGTTGTGAAAAATAGAGGGGTAACCTCCTAAGCCTTCCCTTTTAAAA 2325
A G N V A O L R E H F V K N R G V T P K P S L L K
GCTGCTTTAATTGCAGGTGCTGCGGATGTTGGACTTGGCTTTCCAAATGGTAACCAAGGATGGGGAAGAGTAACG 2400
A A L I A G A A D V G L G F P N G N O G W G R V T
TTAGATAAATCCCTAAATGTCGCATTTGTGAATGAAACGAGCCCTTTATCAACAAGTCAAAAAGCAACATATTCG 2475
L D K S L N V A F V N E T S P L S T S O K A T Y S
TTTACGGCTCAAGCTGGTAAACCCTTAAAAATATCACTTGTGTTGGTCAGATGCACCAGGTAGCACGACGGCATCA 2550
F T A O A G K P L K I S L V W S O A P G S T T A S
CTAACTTTAGTGAATGATTTAGACTTAGTAATCACTGCACCAAATGGAACATAATACGTCGGAAATGACTTTACA 2625
L T L V N D L D L V I T A P N G T K Y V G N D F T
GCACCGTATGATAACAATTGGGATGGCAGAAACAACGTGGAAAATGTGTTTATCAATGCTCCTCAAAGCGGAACG 2700
A P Y D N N W D G R N N V E N V F I N A P O S G T
TATACAGTCGAAGTGCAGGCTTACAATGTACCAGTAAGTCCGCAAACCTTTTCTTTAGCGATTGTACATTAAAAAT 2775
Y T V E V Q A Y N V P V S P O T F S L A I V H
ATTGGAAGGAAGAGTTGTTGATGAATATATCAGCAGCTCTTTTTTTGATTAAGCTCTTTTCGTAAAGGTTGTTGC 2850
TTTAAGTCGGTAAAAAGTCGGTATTTGGACTTTTACCAGTCATTTTGCTTGGGAAATTGATGAGAGTACTTTCA 2925
TTACTGATGGAAAAGAGCAGGATTGCAACGTTTATGACGGGTGATTTCTATTTACGAAAAGCAACAAAGTATGC 3000
GAAA 3004

Fig. 5B


```

1 MRKKGSKRVFLSVLSVAALLSSVALSSPSTIGANNFELDFKGIETLTLEKAAT  

| |+|||-|||+--|||+||-||-||-++|+++|+|+++|--+--+  

1 MKGKKRVVLSVVASAAILASVMVSSP.TSGA.DFQVNFGVKSL.NASLV  

54 KQGKTGKASFLVNSENVKIPKSIQKKLEVVPADNKLYIVQFDGPPILEETQLQL  

|--++|+|||++|++|||+|||+|--|+|||+|-||-||-+-+--|  

50 KPISSGEASFVLDTENINIPKGIQKKLEAVQKDNELYIVQFTGPISEEERKGL  

107 EKTGAKILDYIPDYAYIVEYDGDVKAVTNAIAHLESVEPYLPLYKIDPQLFSR  

|+-|++|||+|||+|||+||-+|---+---+|+|+|+|||+|+++  

103 ESLGVSILDYVPDYAFIVQYSCATKNIS.TLHSVENVQPFLPLYKIDPELLTK  

160 GASELVETVALDKKQRSKEVRLRGLEQIAQYATNNDVLVYVTPKPEYEVLNDVA  

|||+||++|-|+-|+++|++++-||++|+|||+|||+|||+|||++|||  

155 GASQLVQAVILNTKHENKNMKFTGLDEIVQYAANNDVLYISPKEPEYELMNDVA  

213 RGIVKADVAQNNEGGLYGQQIVAVADTGLDTGRNDSMHAEFRGKITALYALG  

|||+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||  

208 RGIVKADVAQNNGLYGQQQLVAVADTGLDTGRNDSMHAEFRGKITALYALG  

266 RTNNANDPNHGHTHVAGSVLGNATNKGMAPQANLVFQSIMDSGGGLGGLPANL  

|||+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||  

261 RTNNASDPNHGHTHVAGSVLGNALNKGMAPQANLVFQSIMDSGGGLGGLPSNL  

319 QTLFSQAYSAGARIHTNSWGAPVNGAYTTDSRNVDYVRKNDMTILFAAGNEG  

+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||  

314 NTLFSQAWNAGARIHTNSWGAPVNGAYTANSRQVDEYVRNNDMTVLFAAGNEG  

372 PGSGTISAPGTAKNAITVGATENLRPSFGSYADNINHVAQFSSRGPTRDGRIK  

|+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||  

367 PNSGTISAPGTAKNAITVGATENYRPSFGSIADNPNIHQFSSRGATRDGRIK  

425 PDVMPAGTYILSARSSLAPDSSFWANHDSKYAYMGGTSMATPIVAGNVAQLRE  

|||-|||+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||  

420 PDVTAPGTFILSARSSLAPDSSFWANYNSKYAYMGGTSMATPIVAGNVAQLRE  

478 HFVKNRGVTPKPSLLKAALIAGAADVGLGFNGNQGWGRVTLDKSLNVAFVNE  

||+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||  

473 HFIKNRGITPKPSLIKAALIAGATDVGLGYPSGDQGWGRVTLDKSLNVAFVNE  

531 TSPLSTSQKATYSFTAQAGKPLKISLVWSAPGSTTASLTLVNDLDELVITAPN  

++-|+|+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||  

526 ATALATGQKATYSFQAQAGKPLKISLVWTDAFGSTTASYTLVNDLDELVITAPN  

584 GTKYVGNDFTAPYDNNDGRNNVENVF INAPQSGTYTVEVQAYNVPVSPQTFS  

|-|||+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||+|||  

579 GQKYVGNDFSYPYDNNDGRNNVENVF INAPQSGTYIIEVQAYNVPSGPQRFS  

637 LAIVH  

|||||  

632 LAIVH

```

Fig. 6B

JP170 vs. subtilisin

1 MRKKGSKRVFLSVLSVAALLSSVALSSPSTIGANNFELDFKGIETLTLEKAATKQG

57 KTGKASFLVNSENVKIPKSIQKKLEVVPADNKLYIVQFDGP ILEETQLQLEKTGAK

1 MKRSGKIFTTAMLAVTLM

113 ILDYIPDYAYIVEYDGDVKAVTNAIAHLESVEPYLPLYKIDPQLFSRGASELVETV

20 MPAIGVSANRGNAADGNEKFRVLVDSANQNNLKNVKEQYGVHWDFAGEGFTTNMNE

169 ALDKKQRSKEVRLRGLEQIAQYATNNDVLYVTPKPEYEV LNDVARGIVKADVAQNN

76 KQFNALQNNKNLTVEKVPELEIATATNKPEALYNAMAASQSTPWGIKAIYNNNSNLT

225 FGLYGQGQIVAVADTGLDTGRNDSSMHEAFRGKITALYALGR TNNANDPNHGTHV
| - | - - + | | - | | + + | + + - | - | - + + + - - - | - - + + + - - - - | + + + | - + | | | | |

132 STSGGAGINIAVLDTGVNTNHPDLS.NNVEQCKDFTVGTNFTD NSCTDRQGHGTHV

281 AGSVLGN.AT.N..KGMAPQANL.VFQSIMDSGGGLG.GLPANLQ TLF SQAYSAGA
| | | + | + | - + | - + - - - | + | | + | + | - + + + - - - | + | + | - + - - - + + - - - + | | - + - + +

187 AGSALANGGTGSGVYGVAPEADLWAYKVLGDDGSGYADDIAEAIRHAGDQATALNT

331 RIHTN.SWGAPVNGAYTTDSRNVDDYVRKNDMTILFAAGNEGPGSGTISAPGTAKN
+ + - - | - | - | + - - + + + - - | + + - - | - | | + - - + - - - | + - | | | | + | - - | + | + - | | + - - |

243 KVVINMSLGSSGESSLITNA..V.DYAYDKGVLIIAAGNSGPKPGSIGYPGALVN

386 AITVGATENLRPSFGSYADNINHVAQFSSRGPTRDGRIKPDVMA PGTYILSARSSL
| + + | + | - | | - - - + - | + | - - - - - + | | + | | | | - - | - - - - - - | + - - | - - - + | | - - - +

296 AVAVAALENTIQN.GTY....RVADFSSRGHKR..TAGDYVIQKGDVEISA.PGA

442 APDSSFWANHDSKYAYMGGTSMATPIVAGNVAQLREHFVKNRGVTPKPSLLKAALI
| - - - | - | - - - | + - | | - + + | | | | + | - + | | - + | + +

343 AV.YSTW..FDGGYATISGTSMASPHAAGLAAKIWAQSPAASNVDVRGELQTRASV

498 AGAADVGLGFPNGNQGWGRVTLDKSLNVAFVNETSPLSTSQKATYSFTAQAGKPLK

396 NDILSGNSAGSGDDIASGFGFAKVQ

554 ISLVWSDAPGSTTASLTLVNDLDLVITAPNGTKYVGNDF TAPYDNNWDGRNNVENV

610 FINAPQSGTYTVEVQAYNVPVSPQTFSLAIVH




Fig. 7




Fig. 8




Fig. 9




Fig. 10


Applicant's or agent's file reference number	5251.204-WO	International application TBA	PL 98/12005
---	-------------	----------------------------------	-------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13 bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>43</u> , line <u>9</u>	
B. IDENTIFICATION OF Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depository institution Agricultural Research Service Patent Culture Collection (NRRL)	
Address of depository institution (including postal code and country) Northern Regional Research Center 1815 University Street Peoria, IL 61604, US	
Date of deposit April 4, 1997	Accession Number NNRL B-21680
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect of those designations in which a European and/or Australia Patent is sought, during the pendency of the patent application, a sample of the deposited microorganism is only to be provided to an independent expert nominated by the person requesting the sample (Rule 28(4) EPC/Regulation 3.25 of Australia Statutory Rule 1991 No. 71).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indication listed below will be submitted to the International Bureau Later (specify the general nature of the indications e.g. "Accession Number of Deposit")	

For receiving Office use only

<input checked="" type="checkbox"/> This sheet was received with the international application
Authorized officer 

For International Bureau use only

<input type="checkbox"/> This sheet was received with the International Bureau on:
Authorized officer

AMENDMENT TO JOINT DEVELOPMENT AGREEMENT

This Amendment is to the Joint Development Agreement between Kraft Foods North America, Inc. and Novozymes A/S, signed April 15, 2003 and April 9, 2003, respectively. Kraft and Novozymes agree to amend the Agreement as set forth below. This Amendment is effective as of the last date signed below.

I. Non-Dairy Beverages, Meat and/or Fish

Although the parties disagree whether food or beverages which do not contain milk-derived ingredients prior to addition of LBA are "Dairy Product(s)" and are within the "Field" of the Agreement, the parties nevertheless desire to exchange confidential information related to the fields of (i) the enzymatic conversion of lactose in pure and/or crude form as derived from or contained in a dairy product, into LBA in pure and/or crude form, for use of said LBA in non-dairy beverages and (ii) the enzymatic conversion of lactose in pure and/or crude form as derived from or contained in a dairy product, into LBA in pure and/or crude form, for use of said LBA in meat and/or fish in order to explore whether the parties are interested in collaborating with each other in these fields. The parties agree that such confidential information shall be deemed "Confidential Information" subject to Article 9 of the Agreement.

This agreement to exchange such confidential information and the exchange of such confidential information under Article 9 of the Agreement shall not, however, be construed as an agreement or waiver that food or beverages which do not contain milk-derived ingredients prior to addition of the LBA, and specifically, that non-dairy beverages, meat and/or fish are "Dairy Product(s)" that either fall within or outside of "Field" of the Agreement.

II. Extension of Time Periods of the Agreement

The parties agree to extend by a period of one year (i) the minimum annual payment dates set forth in Article 7.A.5, (ii) the GRAS status and commercial supply dates set forth in Article 7.A.7, (iii) the scale up Specific Enzyme date set forth in Article 11.7 and (iv) the Commercialization date set forth in Article 11.11. Accordingly, Articles 7.A.5, 7.A.7, 11.7 and 11.11 are deleted and replaced as follows:

7.A.5. If Kraft or Kraft Customers in total do not pay to Novozymes the sums identified in this paragraph below and/or do not buy Enzyme for use within the Full-Exclusive Kraft Sub-Fields and/or Time-Limited Exclusive Sub-Fields from Novozymes in a total amount of one million (1.0) United States Dollars in 2006, one point nine (1.9) million United States Dollars in 2007, and two point four (2.4) million United States Dollars in 2008 and for the following years in an amount to be agreed to by the Parties in accordance with Article 7.A.8, then Novozymes shall have the right to convert all the Full-Exclusive Kraft

Sub-Fields and all the Time-Limited Exclusive Sub-Fields into Non-Exclusive Sub-Fields. Kraft, however, may invoke the process outlined in Article 7.A.6 below to prevent Novozymes from making such conversion of the Time-Limited Exclusive Sub-Fields and Full Exclusive Kraft Sub-Fields to Non-Exclusive Sub-Field.

7.A.7 Notwithstanding the due dates for minimum purchase and payment obligations provided in 7.A.5, if: a) Kraft has diligently sought the required GRAS status, and the appropriate GRAS status has not been confirmed by June 30, 2005 in accordance with Article 3B.2; b) Novozymes has not obtained GRAS status confirmation in accordance with Article 3A.2 by December 31, 2005; or c) Novozymes is unable to supply to Kraft commercial quantities of Enzyme of a quality agreed upon by the Parties; such that Kraft cannot proceed to Commercialization in a Full-Exclusive Kraft Sub-Field or Time-Limited Kraft Sub-Field, the minimum purchase and payment obligations detailed in Article 7.A.5 will be delayed by a number of days equal to the number of days delay in obtaining all of a)-c). For example, if GRAS status is delayed by 90 days, Kraft will still be required to pay the minimum purchase and payment amounts, however, the minimum purchase and payment requirements will not begin to accrue until 90 days after the beginning of 2006, 2007 and 2008, respectively.

11.7 Kraft may terminate this Agreement upon written notice to Novozymes in the event that Novozymes, despite its best efforts, has not sufficiently scaled up Specific Enzyme manufacturing process to supply Kraft with commercial quantities of Specific Enzyme of the quality agreed upon by the Parties by June 30, 2006, or at least (60) days before Kraft's Commercialization, whichever date is later in time, provided that Novozymes failure to sufficiently scale up its Specific Enzyme is not due in full or in part to Kraft's significant delays in the amount of thirty (30) days or more, Kraft's lack of diligence in meeting its duties and obligations hereunder, or other fault of Kraft or Kraft's Customers.

11.11 Novozymes may terminate this Agreement upon written notice to Kraft in the event that Kraft does not Commercialize on or before December 31, 2007, unless such lack of Commercialization is due in full or in part to Novozymes' significant delays in the amount of thirty (30) days or more, Novozymes' lack of diligence in meetings its duties and obligations hereunder, or other fault of Novozymes or Novozymes' suppliers.

III. Amendments to Article 7 "PRINCIPLES OF BUY AND SUPPLY"

Article 7.1(b) is deleted and new article 7.1 (b) is added, as follows:

7.1 (b) An initial Enzyme price range of USD 0.55 - USD 0.60 per pound of LBA generated by the Enzyme applies to Process Cheese. This price includes both Enzyme and catalase. This price is based on the assumption that the Enzyme dose does not exceed 0.5 U/ml, catalase dose does not exceed 0.3 g/L, lactose substrate is provided as a permeate at 50 g/ml, and the conversion factor is at least 90% in 18 hours, using an isomix air sparging and agitation system. The Parties agree that the Enzyme and catalase price per pound of LBA will be converted to a price per pound of Enzyme and catalase during Buy and Supply Agreement negotiations.

This price is based on the assumption that Novozymes shall not need to perform any additional purification step(s) of either Enzyme and/or catalase for supply to Kraft and Novozymes can eliminate the downstream heat treatment step which was introduced in the Spring of 2004 for producing Enzyme for supply to Kraft.

Although the catalase currently supplied by Novozymes to Kraft is not derived from a genetically modified organism (GMO), in the event that Novozymes develops a GMO derived catalase, Kraft shall accept this GMO derived catalase from Novozymes as the catalase for supply and purchase under the Agreement, provided the performance of the catalase is similar according to reasonable performance criteria agreed upon by the parties.

Articles 7.A.3 and 7.A.4 are deleted, and new articles 7.A.3 and 7.A.4 are added as follows:

7.A.3 Time-Limited Exclusive Sub-Fields:

For the Time-Limited Exclusive Sub-Fields and upon a decision for Commercialization, Kraft agrees to purchase Enzyme exclusively from Novozymes for use within the Time-Limited Exclusive Sub-Fields and Novozymes agrees to supply Enzyme exclusively to Kraft for use within the Time-Limited Exclusive Sub-Fields, unless otherwise agreed to in writing by the Parties. In order for Kraft to maintain its Time-Limited Exclusive Sub-Fields, Kraft or Kraft Customers must: a) purchase from Novozymes the minimum annual amounts of Enzyme in U.S. Dollars identified in Article 7.A.5; b) pay to Novozymes the amounts identified in Article 7.A.5; or c) combine a) and b) to satisfy the total annual amounts identified in Article 7.A.5.

Kraft shall not sell outside of Kraft, except as specified below, LBA generated from the enzymatic conversion (by use of an Enzyme) of lactose in pure form and/or crude form for use as an ingredient, either directly or indirectly, in the Time-Limited Exclusive Sub-Fields, except that Kraft may sell a maximum of 10% of the Kraft yearly production of LBA generated from the enzymatic conversion (by use of an Enzyme) of lactose in pure form and/or crude form for the

purpose of managing Kraft LBA inventory. However, should Kraft sell such LBA outside of Kraft, the price of Enzyme shall then be increased according to Article 7.1(a) to account for such sales. Kraft shall provide a quarterly statement to Novozymes of the volumes and the use for which such LBA was sold outside of Kraft.

7.A.4 Non-Exclusive Sub-Fields:

For the Non-Exclusive Sub-Fields, Kraft has no obligation to buy Enzymes from Novozymes for use in Non-Exclusive Sub-Fields. Kraft shall have the right to buy Enzymes from third parties for use in Non-Exclusive Sub-Fields provided such Enzymes do not fall within the scope of Novozymes' Background Patent for the term of such Patents. Novozymes shall have the right to sell Enzymes to third parties for use in Non-Exclusive Sub-Fields. However, Novozymes shall sell Enzyme to Kraft if Kraft wants to buy Enzyme from Novozymes for use in Non-Exclusive Sub-Fields.

Kraft shall not sell outside of Kraft, except as specified below, LBA generated from the enzymatic conversion (by use of an Enzyme) of lactose in pure form and/or crude form for use as an ingredient, either directly or indirectly, in the Non-Exclusive Sub-Fields, except that Kraft may sell a maximum of 10% of the Kraft yearly production of LBA generated from the enzymatic conversion (by use of an Enzyme) of lactose in pure form and/or crude form for the purpose of managing Kraft LBA inventory. Such maximum of 10% of Kraft yearly production of LBA is inclusive of and not additive to the maximum of 10% of the Kraft yearly production of LBA recited in Article 7.A.3.

IV. Article 11 "TERMINATION AND SURVIVAL OF PROVISIONS"

Article 11 is amended to include the following new termination clause:

- 11.16** A Party may request to terminate this Agreement by providing sixty (60) days prior written notice substantiated by reasonable written documentation of lack of financial and/or technical feasibility of all Development Plan(s). If the parties mutually agree in writing that the Agreement should be terminated for financial and/or technical reasons, upon such termination Article 5, Article 6.A, Article 7, Article 9, Article 10, Article 11 (excluding Articles 11.7, 11.8, 11.9, 11.10, 11.11, 11.12, 11.13 and 11.15, which are voided upon execution of termination clause 11.16), Article 17, Article 18, Article 19, Article 20, Article 22, and Article 23 shall survive. Article 6 and Article 7.A shall survive as amended below upon execution of termination clause 11.16. Although Article 8 does not survive, for clarification, Novozymes shall not receive a license under Kraft's WO 02/089592 or any and all corresponding patents and patent applications thereof for Process Cheese.

Article 6 survives and is unchanged except that Article 6.6 is deleted and replaced with the following new Article 6.6:

6.6 Any new Sub-Field not identified in Article 6.1 prior to termination under 11.16 shall be designated as a “Non-Exclusive Sub-Field,” and shall have been deemed designated as a “Non-Exclusive Sub-Field” prior to termination under 11.16 and treated as such under the Agreement and after termination under 11.16 under the surviving articles of the Agreement.

7.A SALE AND PURCHASE OBLIGATIONS (AS AMENDED UPON EXECUTION OF TERMINATION CLAUSE 11.16)

7.A.1. Full-Exclusive Kraft Sub-Fields (As Amended Upon Execution of Termination Clause 11.16):

For the Full-Exclusive Kraft Sub-Fields and upon a decision for Commercialization, Kraft agrees to purchase Enzyme exclusively from Novozymes for use within the Full-Exclusive Kraft Sub-Fields and Novozymes agrees to supply Enzyme exclusively to Kraft for use within the Full-Exclusive Kraft Sub-Fields, unless otherwise agreed to in writing by the Parties.

7.A.2 Full-Exclusive Novozymes Sub-Fields (As Amended Upon Execution of Termination Clause 11.16):

For the Full-Exclusive Novozymes Sub-Fields, Novozymes shall have the freedom to sell Enzyme(s) exclusively (or non-exclusively at Novozymes’ choice) to third parties and does not have an obligation to sell to Kraft. Kraft has no obligation to purchase Enzyme from Novozymes for use in the Full-Exclusive Novozymes Sub-Fields.

7.A.3 Time-Limited Exclusive Sub-Fields (As Amended Upon Execution of Termination Clause 11.16):

For the Time-Limited Exclusive Sub-Fields and upon a decision for Commercialization, Kraft agrees to purchase Enzyme exclusively from Novozymes for use within the Time-Limited Exclusive Sub-Fields and Novozymes agrees to supply Enzyme exclusively to Kraft for use within the Time-Limited Exclusive Sub-Fields, unless otherwise agreed to in writing by the Parties. For the avoidance of any doubt, after expiration of the Lead-time, when the Time-Limited Exclusive Sub-Fields are converted into Non-Exclusive Sub-Fields, sale and purchase obligations are according to Article 7.A.4

7.A.4 Non-Exclusive Sub-Fields (As Amended Upon Execution of Termination Clause 11.16):

For the Non-Exclusive Sub-Fields, Kraft has no obligation to buy Enzymes from Novozymes for use in Non-Exclusive Sub-Fields. Kraft shall have the right to buy Enzymes from third parties for use in Non-Exclusive Sub-Fields provided such Enzymes do not fall within the scope of Novozymes' Background Patent for the term of such Patents. Novozymes shall have the right to sell Enzymes to third parties for use in Non-Exclusive Sub-Fields. However, Novozymes shall sell Enzyme to Kraft if Kraft wants to buy Enzyme from Novozymes for use in Non-Exclusive Sub-Fields.

7.A.5 Deleted Upon Execution of Termination Clause 11.16

7.A.6 Deleted Upon Execution of Termination Clause 11.16

7.A.7 Deleted Upon Execution of Termination Clause 11.16

7.A.8 Deleted Upon Execution of Termination Clause 11.16

7.A.9 Notwithstanding anything herein, including those Articles herein which govern the termination of Full Exclusive Kraft or Novozymes Sub-Field(s), within the EU and EEA, all exclusivities within Full-Exclusive Kraft or Novozymes Sub-field(s) obtained pursuant to this Agreement shall at a maximum be in force for seven (7) years after the Enzyme has been put on the relevant market. However, if agreed by the Parties and if lawfully possible in accordance with regulations of the European Union Block Exemption, then exclusivity granted in this Agreement within the EU and EEA for a longer period may be maintained after those seven (7) years in accordance with this Agreement.

V. Stand-By of the Milestones and Payments

Provided the Agreement is still in force, the parties may agree in writing to a reasonable delay and/or extension of any time period(s), due date(s), right(s), requirement(s), obligations of the parties as provided for under the Agreement, for example, so as to permit time for the parties to carryout new Development Plan(s) or to identify/explore new Sub-Fields for joint development under the Agreement. For example, the parties may mutually agree in writing to further delay the due date for any minimum payment obligation required by Kraft under Article 7.A.5, the due dates for GRAS status and commercial supply under Article 7.A.7, the due date for the scale up Specific Enzyme under Article 11.7 and the Commercialization date under Article 11.11.

All other articles/sections of the Agreement are unchanged.

The Parties have duly executed this Amendment by their authorized representatives below.

Novozymes A/S

Kraft Foods North America, Inc.

By:
Title:
Date:

By:
Title:
Date: